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Abstract  
This thesis investigates the previously un-described role of Dmrt5, a zinc-finger 
transcription factor, in ventral midbrain development. The spatio-temporal expression 
pattern of Dmrt5, described for the first time in this thesis, suggests that Dmrt5 may 
have a role in midbrain dopaminergic development. 
Exogenous expression of Dmrt5, by in ovo electroporation in the chick embryo and 
over expression during neuronal differentiation of mouse epistem cells, causes 
ectopic expression of Hes1, a gene involved in the timing of neurogenesis. Dmrt5 
ectopic expression also reduces the number of cells undergoing proliferation and 
inhibits terminal differentiation. These findings are consistent with the previously 
described phenotype observed upon Hes1 over expression. Studies in neuronal 
progenitors derived from mouse epistem cells indicate Dmrt5 mediates this effect by 
binding to the Hes1 promoter region.  
Genome-wide analysis of Dmrt5 over expression within the developing chick 
embryo, implicate Dmrt5 in specification of dorsal-ventral patterning. Dmrt5 promotes 
a floor-plate-like transcriptional profile when it is ectopically expressed in the dorsal 
ventral lateral midbrain. This observation is confirmed by ectopic expression studies 
in the developing chick and by over expression studies in neural progenitors 
differentiated from mouse epistem cells.  
In conclusion the data presented in this thesis describe the role of Dmrt5 in 
neurogenesis and dorsal-ventral patterning of the ventral midbrain. This data 
contributes to our knowledge of the developmental program involved in the creation 
of midbrain dopaminergic progenitors.  
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Chapter 1. Introduction 
 
1.1 Dopamine neurons  
Neurons producing the catecholaminergic neurotransmitter dopamine are present in 
various areas of the central nervous system (CNS), as illustrated in Figure 1.1. They 
are typically identified by the presence of tyrosine hydroxylase (TH), the rate limiting 
enzyme for dopamine biosynthesis.[1, 2] 
The largest population of dopaminergic neurons in the brain are found in the ventral 
midbrain. The majority of these midbrain dopaminergic neurons form the substantia 
nigra pars compacta (SNc, or A9 group) and the ventral tegmental area (VTA, A10 
group), with the remaining midbrain dopamine neurons found in the retrorubral field 
(RrF, A8).  These midbrain dopamine neurons project to the striatum, limbic and 
cortical areas forming the nigro-striatal, meso-limbic and meso-cortical pathways. 
(Figure 1.1) [3, 4] 
Although the majority of dopamine neurons are found in the midbrain there are 
populations of dopamine neurons in the diencephalon involved in neuroendocrine 
control. These diencephalic dopamine neurons, known as the A11-15 groups, 
include dopamine neurons of the posterior hypothalamus (A11) which project to the 
autonomic areas of the lower brain stem and spinal cord [5, 6], and the zona incerta 
in the ventral thalamus (A13) which project diffusely to different areas of the 
hypothalamus and to the amygdala [7, 8]. There is also a small population of 
dopamine neurons in the telencephalon, the A16 group of the olfactory blub 
periglomerular interneurons that serve to modulate sensory activation in the olfactory 
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bulb [9-11]and the A17 group of retina amacrine interneurons involved in adaptation 
to light and dark [12, 13]. (Figure 1.1) 
 
 
Figure 1.1. Location of dopamine neurons cell groups in the adult rodent brain. 
Distribution of dopamine neuron cell groups in the adult brain. The numbering of these cell 
groups was introduced by Dahlström and Fuxe in 1964 [2]. Image is taken from Björklund 
and Dunnett [14].  
 
There is much interest in the midbrain dopaminergic neurons of the SNc and VTA, 
which function in motor control, reward and emotive behaviour, as their dysfunction 
and degeneration is involved in several diseases [15]. Preferential degeneration of 
SNc neurons projecting to the striatum leads to the characteristic symptoms of 
Parkinson’s disease (PD), namely hypokinesia resting tremor and rigidity [16-18]. 
This disease is one of the most common neurodegenerative diseases, affecting 
about 2% of the population over 65 years [19, 20]. The cause of the 
neurodegeneration seen in PD patients is largely unknown, with the majority of the 
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cases being sporadic [21, 22]. To date (2011), more than 10 genes and several 
additional genetic loci have been associated with familial forms of the disease [22-
29]. These indicate that abnormally increased oxidative stress and mitochondrial 
dysfunction, together with protein misfolding and impairments in the ubiquitin–
proteasome and autophagy–lysosomal systems contribute to PD [19, 30, 31]. 
PD patients are currently treated with a variety of pharmacological tools, including L-
DOPA, dopaminergic agonists and inhibitors of dopamine degrading enzymes [17, 
19, 32]. The current surgical treatment of PD is mainly based on the use of deep 
brain stimulation of the internal segment of the globus pallidus, the subthalamic 
nucleus or the pedunculopontine nucleus [33]. While these treatments provide 
symptomatic relief, none of them change the course of the disease [34]. There is 
therefore a clear need for restorative and regenerative approaches.  
The discovery in the rat that foetal dopamine neurons from the ventral midbrain can 
be transplanted into 6-hydroxydopamine lessioned dorsal striatum and restore 
impaired motor functions [35] led to the experimental use of dopamine grafts in 
individuals with Parkinson’s disease as a possible restorative method [36-41] [42]. In 
clinical trials dopamine-producing human foetal midbrain tissue was transplanted into 
the striatum of PD patients. Patients in some trials have shown increased numbers 
of dopamine neurons within the nigro-striatal pathway and improvements in general 
motor performances [36-41], however the results are inconsistent [43-46]. Despite 
their inconsistencies, these trials provide proof of principle that replacement therapy 
may provide a prophylactic treatment for PD. However use of foetal tissue for 
transplantation, as a routine treatment, is both impractical and unethical. Meanwhile, 
grafting of embryonic stem (ES) [47-52] and neural stem (NS) cells [52-54] into the 
striatum of animals with PD characteristics to improve motor symptoms has proved 
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unsuccessful. This highlights the need to use cells which already exhibit midbrain 
dopaminergic identity [55-57]. As a result there is great interest in creating midbrain 
dopaminergic neuronal progenitors from pluripotent cells in vitro. 
In addition to degeneration of the nigro-striatal projection causing PD, dysregulation 
of dopamine synaptic transmission in the meso-limbic system has also been linked 
to the development of drug addiction [58-60] and depression [61]. Exaggerated 
forebrain (meso-cortico-limbic projections) dopamine transmission is thought to 
contribute to psychotic symptoms of schizophrenia [62, 63], which has a worldwide 
incidence of 15 per 100,000 [64]. Addiction, depression, neurodegenerative diseases 
and schizophrenia, all major public health problems of the industrialised world, are 
linked to degeneration or dysfunction of the ventral midbrain dopaminergic neurons 
of the SNc and VTA. Therefore understanding the behaviour of these neurons is of 
major importance.  
The non-proliferative nature of neurons and the inaccessibility of this population 
mean further study of midbrain dopamine neurons requires generation of these 
neurons in vitro. These created neurons would be useful for a number of 
applications, such as: pharmacological assays to analyse the activity of potential 
drug treatments for midbrain dopaminergic system disorders, comparative studies of 
diseased neurons derived from patient cells and healthy neurons to identify possible 
mechanisms and causes of the disease. Finally, as studies in animal models have 
indicated that transplantation of dopaminergic neurons into the SNc can alleviate the 
motor symptoms of PD [35, 36]; the generation of these neurons from stem cells or 
induced pluripotent patient cells could provide a potential therapy for this increasingly 
prevalent disease. 
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To create functional midbrain dopaminergic neurons, which resemble in vivo 
counterparts, from pluripotent cells in vitro, it is thought that a cascade of 
transcription resembling normal in vivo development must be triggered. Current in 
vitro differentiation methods mimic the known in vivo developmental pathways, but 
still give low yields of dopaminergic neurons with many not displaying an authentic 
dopaminergic profile [65-67]. To improve in vitro generation of dopamine neurons a 
better understanding of midbrain dopaminergic neuron specification and 
development is required. Our current understanding of midbrain dopaminergic 
neuronal development is discussed below, followed by a summary of in vitro 
generation methods currently used. 
 
1.2 Development of midbrain dopaminergic neurons 
Dopaminergic neurons arise in the ventral midbrain. Formation of this region is 
mediated by two signalling centres, the isthmus (IsO) which determines the 
Anterior/Posterior (A/P) axis of the midbrain, and the floor plate which defines the 
Dorsal/Ventral (D/V) axis. These signalling centres potentiate cells located in the 
medial ventral midbrain to dopaminergic fate by triggering expression of specific 
transcription factors. Following specification, differentiation of these progenitors 
results in the formation of mature midbrain dopaminergic neurons. In the following 
sections I will discuss these 3 steps.  
1) Formation of the ventral midbrain and potentiation of dopaminergic neurons 
2) Specification to dopaminergic fate 
3) Terminal differentiation 
20 
 
1.2.1 Formation of the midbrain by A/P and D/V patterning leads to 
potentiation of the ventral midbrain to dopaminergic fate  
After its formation, the neural plate is sub-divided into restricted domains. This 
results in formation of the midbrain, forebrain, hindbrain, and spinal cord regions of 
the neural epithelium. With regard to formation of the midbrain, this is determined by 
formation and positioning of the IsO at the midbrain-hindbrain border and the floor 
plate at the ventral midline, both of which express signalling factors required for 
midbrain dopaminergic neuron development [68, 69]. 
 
1.2.1.1 Formation of the isthmus 
The isthmus (IsO) locates the junction between the midbrain and hindbrain, it is 
necessary and sufficient for development of the midbrain and hindbrain structures 
[70-72]. Transplantation of the tissue encompassing the IsO to another region of the 
neural tube can induce midbrain and hindbrain cell fate in host territories [71-75]. 
Conversely, if neural tissue, such as the prosencephalic tissue, is grafted into the 
IsO this acquires midbrain and hindbrain cell fates [76, 77], while removing the IsO 
triggers loss of midbrain and hindbrain structures [78]. The IsO controls the rostro-
caudal specification of the midbrain and hindbrain as grafting and transplantation 
experiments showed that the induction of midbrain or hindbrain is always polarised 
[71-73, 75-77].  
At the onset of somitogenesis paired box gene 2 (Pax2) and wingless-type MMTV 
integration site family member 1 (Wnt1) are expressed in broad and overlapping 
domains within the IsO [79], with Wnt1 restricted to the midbrain side and Pax2 [80] 
followed by En2 (at 3-5 somite stage) and paired box gene 5 (Pax 5) (3-5 somite 
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stage) expressed across the isthmus border [81-83]. The secreted factor, fibroblast 
growth factor 8 (FGF8), is expressed at the 3-5 somite stage, but is restricted to the 
caudal hindbrain [80]. The boundaries between the midbrain and hindbrain are 
subsequently refined to form the IsO. At this point Wnt1 expression is down 
regulated such that it is now only present in a ring of cells in the neural tube just 
rostral to the IsO [84-86]. These observations regarding the formation of the 
boundary between the midbrain and hindbrain indicate that this IsO is roughly 
positioned during late gastrulation and then is progressively refined during early 
somitogenesis. Complete or partial loss of Wnt1 and FGF8, which are expressed on 
either side of the IsO, leads to a gradual loss of midbrain and hindbrain, indicating 
these genes control the maintenance of the IsO [86-92].  
 
1.2.1.2 Floor plate provides dorsal ventral patterning 
Formation of the ventral midline occurs when the neural plate undergoes neurulation. 
During this process the most lateral regions of the neural tissue of the neural plate 
are elevated, this leads to bending of the neural plate and formation of a neural 
groove. The medial movement of the neural folds towards the midline causes the two 
sides of this neural tissue to meet and fuse, sealing the neural tube [93, 94]. The 
notochord lies directly under the midline and expresses Sonic Hedgehog (Shh); this 
expression induces Shh expression in the floor plate [95-102] 
1.2.2 Potentiation of ventral midbrain 
Midbrain dopaminergic neurons arise from the Shh expressing region of the floor 
plate, rostral to the IsO [103-107]. Indeed co-culture of explant of E9 rat floor plate 
with dorsal midbrain can induce ectopic dopaminergic neurons [95]. The inductive 
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effects of the floor plate can be mimicked by graded doses of Shh [69, 95, 99, 108-
110], and its effects are prevented by Shh-blocking antibodies [69], suggesting that 
Shh is responsible for the observed floor plate activity and that this is involved in 
formation of midbrain dopaminergic neurons.  
Whilst Shh is expressed within the floor plate of the entire neural tube, dopaminergic 
neurons are only found in the midbrain, suggesting that Shh alone is not sufficient for 
dopamine neuron generation [103, 105, 106]. Moreover, exposure to exogenous Shh 
cannot induce ectopic dopaminergic neurons in the hindbrain, ventro or dorsocaudal 
forebrain [69]. In a similar pattern, loss of FGF8 from E9 midbrain floor plate explants 
prevents formation of dopaminergic neurons, despite normal Shh expression [69]. 
However, the IsO or FGF8 alone are not sufficient to induce dopamine neurons in 
the absence of Shh [69]. Rather the integration of anterior-posterior and dorsal-
ventral patterning information of the IsO and floor plate respectively are required in 
order to create dopamine neurons [69]. This FGF8 and Shh co-expressing region 
which gives rise to midbrain dopaminergic neurons is shown in Figure 1.2.  In 
support of this hypothesis, ES cells exposed to FGF8 and Shh differentiate to 
midbrain dopaminergic fate [65, 111, 112]. It is important to note that whilst this 
potentiation process enables cells to become dopaminergic it does not commit them 
solely to this fate. 
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Figure 1.2. Schematic representation of potentiation of midbrain dopaminergic 
neurons in a horizontal plane. Co-ordinate signalling of FGF8 from the isthmus (blue) and 
Shh signalling from Floor plate (red) induce midbrain dopaminergic progenitors in the ventral 
midbrain (orange). Image represents mouse E8.0 or chick HH st 10.  
 
 
 
 
The signalling from the IsO and floor plate convey specific neuronal identity to the 
ventral midbrain cells by triggering the expression of specific transcription factors 
which specify dopaminergic fate to the most medial population, these transcription 
factors will be discussed in the next section. Figure 1.3 depicts the developing brain, 
highlighting the region which gives rise to midbrain dopaminergic neurons. 
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Figure 1.3. Schematic view of developing brain. Midbrain dopaminergic neurons arise 
from the region in orange due to signalling of FGF8 from the isthmus (blue), Wnt1 signalling 
(green) and Shh signalling from the floor plate (red) and notochord (purple). (B) Coronal 
section through the midbrain, highlighting, in orange, the region from which midbrain 
dopaminergic neurons arise.  
 
1.2.3  Specification of neurons to dopaminergic fate 
Specification commits potentiated cells to midbrain dopaminergic fate and occurs in 
the ventricular zone from around E9.5 onwards (Figure 1.3). The known key players 
in this process are the transcription factors LIM homeobox transcription factor 1 A/B 
(Lmx1A/B), Forkhead box A1/2 (FoxA1/2), Neurogenin2 (Ngn2), Msh homeobox 1/2  
(Msx1/2), and Orthodenticle homeobox 2 (Otx2) [103, 105, 113-119] whose 
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expressions are triggered by the signalling of Wnt1 and FGF8 from the IsO and Shh 
from the FP [69, 107, 120-122]. 
In order to commit the cells to a dopaminergic phenotype, the midbrain dopaminergic 
specification genes block expression of genes involved in the specification and 
neurogenesis of the more lateral midbrain fate, such as the immediately adjacent 
Red Nucleus (RN) by inhibiting expression of genes such as Brna3, Sim and Nkx2.2 
and Nkx6.1, and GABAergic fate by inhibition of Helt [123-125]. As well as blocking 
lateral fates, specification of dopaminergic neurons by Lmx1A/B, FoxA1/2, Otx2, 
Msx1/2, and probably other factors, triggers neurogenesis, which is characterised by 
expression of Ngn2 [114, 117]. 
Neurogenesis within the ventral midbrain occurs from around E10 to E14 in mice 
with the highest rate at E11.5 [126]. Generation of midbrain dopamine neurons 
requires the proneural gene Ngn2, which is expressed in the ventricular and 
intermediate zone [114, 117]. Mash1, which is also expressed at a lower level in the 
ventricular zone, is not required, but can partially compensate for loss of Ngn2 [117]. 
Concomitant with neurogenesis, exit from the cell cycle occurs [127] during this 
process cells move away from the ventricular zone to form the intermediate zone 
[114, 117]. Expression of proneural genes and proliferation seem to be linked as loss 
of Ngn2 prevents cells in the ventricular zone from undergoing cell cycle exit [114, 
117]. 
Thus specification ensures the floor plate region has the correct transcriptional 
profile to create midbrain dopaminergic neurons and to undergo differentiation into 
mature neurons co-expressing TH and Paired homeobox protein 3 (Pitx3). 
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A working model of the gene networks involved in specification can be seen in 
Figure 1.4. Floor plate expression of Shh activates expression of FoxA2 via Gli2 
binding sites on the FoxA2 promoter [120]. FoxA2 then directly activates Shh 
expression leading to a positive feedback loop [128]. FoxA2 is also required for the 
initiation of FoxA1 at E9.5 [125], and conditional loss of FoxA1/2 in neural 
progenitors reduces Lmx1A/B expression [124]. Wnt1 expression from the IsO, 
which signals via the canonical pathway, activates transcription of Lmx1A, Lmx1B 
and Otx2 via β-catenin TCF/LEF sites on the promoter of these genes [121]. It is also 
possible that other canonical Wnts expressed in this region, namely Wnt2 and 
Wnt3A could also be involved in this process [129, 130]. Furthermore Lmx1A directly 
activates transcription of Wnt1 forming a regulatory loop between these two genes 
[121]. 
Following activation of Lmx1A/B, FoxA1/2 and Otx2, expression of further 
transcription factors involved in specification, namely Msx1 directly activated by 
Lmx1A [115, 121] and Ngn2 activated indirectly via Lmx1A , Otx2, Msx1 and FoxA2 
occurs [115, 118, 119, 131]. At the same time expression of the genes required for 
terminal differentiation, > and Pitx3 are initiated directly by Lmx1A/B [121] and by an 
unknown FoxA2 mediated mechanism [118, 124].    
The only known gene sufficient for specification to dopaminergic fate is Lmx1A, as 
ectopic expression of this gene leads to induction of midbrain dopaminergic neurons 
in ES cells and in electroporated chick ventral midbrain [115]. However, Lmx1A only 
has an effect on cells in the ventral midbrain, cells that have been potentiated [115]. 
This is postulated to be because it regulates some targets cooperatively with FoxA2 
and is thus only effective in FoxA2 positive regions [124]. 
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Specifically co expression of Lmx1A and FoxA2 is required for the inhibition of Ngn1 
in the ventral midbrain [123]. Ngn1 is expressed in the more lateral RN [132] and 
inhibits midbrain dopamine fate by repressing Pitx3 [123]. The co-expression of 
FoxA2 and Lmx1A is also required for the inhibition of Shh, the down regulation of 
which may be required to induce neurogenesis in the ventral midbrain at later stages 
of specification. While FoxA2 positively regulates Shh at early stages [120], at later 
stages of specification, Foxa1/2 regulates ventral midbrain patterning by decreasing 
expression of intracellular transducers and downstream targets of Shh in the ventral 
midbrain [125]. Inhibition of this process prevents development of midbrain 
dopaminergic neurons [125].  
Lmx1A alone can indirectly induce Ngn2 which is specifically required to initiate 
neurogenesis towards dopaminergic fate [123]. This is in part by Lmx1A mediated 
repression of Helt (an Ngn2 repressor) normally expressed in more lateral regions 
and which gives rise to GABAergic neurons [123, 132, 133]. Lmx1A has also 
previously been reported to up regulate Ngn2 via directly activating Msx1, which 
inhibits expression of Nkx6.1 [115] another gene found in the adjacent RN region. 
However, the precise role of the repression of Nkx6.1 by Msx1 is not fully 
understood, as over expression of Nkx6.1 does not prevent midbrain dopaminergic 
differentiation [123]. 
In keeping with the role of Lmx1A in repressing the RN fate, Lmx1A also represses 
the FoxA2 induced Sim expression and thereby prevents expression of Lhx1, a gene 
which inhibits differentiation to dopaminergic fate [123]. This indicates that FoxA2 
induces differentiation programs for midbrain dopaminergic neurons but also induces 
a lateral RN fate too. Lmx1A in the ventral midbrain selects the dopaminergic fate by 
suppressing the RN fate. These findings highlight that Lmx1A functions to promote 
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neurogenesis via regulation of Ngn2 and influences patterning [115] to ensure the 
specification of midbrain dopaminergic neurons. 
Lmx1B and 1A are expressed in the same domains and have a 61% conservation of 
amino acid identity [134]. Recent chromatin Immunoprecipitation assays of both ES 
cells and embryonic tissues have shown that like Lmx1A, Lmx1B can bind to the 
promoters of Nuclear hormone receptor 1 (Nurr1), Msx1 and Pitx3 [121]. This may 
explain why knock out of Lmx1A has mild abnormalities in midbrain dopaminergic 
neuron development [123]. While Lmx1B and A seem to regulate many of the same 
target genes, loss of Lmx1B leads to TH cells with no Pitx3 expression at E12.5 and 
an ectopic population of cells that express Pitx3 but not TH [135]. This indicates that 
Lmx1B is required for proper differentiation of midbrain dopaminergic neurons in a 
way which cannot be rescued by Lmx1A. In regard to this, it is important to consider 
that Lmx1B is expressed prior to Lmx1A. The early expression of Lmx1B is involved 
in potentiation of the medial ventral midbrain, therefore in Lmx1B knock out mice this 
role in dopaminergic neuron development could not be compensated for by Lmx1A 
[136, 137].  
Otx2 like Msx1 and Lmx1A can repress expression of genes involved in more lateral 
phenotypes such as the Nkx6.1 and Nkx2.2 genes, expression of which is initiated 
by FoxA2 and Shh. Otx2 repression of these genes ensures differentiation to 
dopaminergic fate, as Nkx2.2 is important in inducing the serotonergic neuronal 
lineage in hindbrain and act as a suppressor of dopaminergic fate [122, 138]. Otx2 is 
integral to midbrain dopaminergic neuron development as conditional loss of Otx2 
during specification results in a severe reduction in the expression of Lmx1A, Msx1, 
and Ngn2 within the ventral midbrain and these cells fail to express Nurr1, 
proliferation defects are also observed [139]. 
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Concomitant with expression of Ngn2 and repression of lateral fates is the 
expression of Nurr1 and Pitx3 which are required for development of the dopamine 
signalling machinery such as transporters and synthesis enzymes [140]. Chromatin 
Immunoprecipitation shows that Lmx1A and 1B can directly activate Pitx3 and Nurr1, 
whilst FoxA2 when expressed in combination with Lmx1A also seems to be involved 
in Nurr1 activation.  This leads to the initiation of the third step in development of 
midbrain dopaminergic neurons, terminal differentiation. 
 
1.2.4 Terminal differentiation of dopaminergic neurons  
Terminal differentiation triggers the expression of all enzymes, transporters and 
receptors required for proper synthesis, storage, release and reuptake of dopamine. 
This includes expression of TH, the rate limiting step for dopamine synthesis, 
aromatic L-amino acid decarboxylase (AADC) needed for the final enzyme in the 
synthesis of dopamine, Vesicular monoamine transporter 2 (VMAT2) involved in 
dopamine storage, and Dopamine Transporter (DAT) involved in dopamine reuptake 
[141]. 
Conventionally, dopaminergic neurons are considered terminally differentiated when 
they express TH. The first TH positive dopaminergic neurons are seen at E10.5 
[142]. However, most terminal differentiation occurs from E12.5 onwards [143]. 
During terminal differentiation the neurons leave the intermediate zone to form the 
marginal zone, from where they migrate to their target tissue. (Figure 1.4) 
In vivo conditional knock out of factors involved in dopamine synthesis and transport 
in dopamine neurons causes no change in the midbrain neuronal development or 
projections, but prevents these neurons from transmitting dopamine to their target 
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tissues correctly [144-146]. This highlights the fact these genes are solely required 
for the functioning of the neurons. Terminal differentiation is mediated by the 
transcription factors Nurr1, Pitx3, and FoxA2, which are initiated during specification 
[118, 141, 147-150]. 
 Nurr1 is required for expression of TH, Vmat2, Ret and DAT, as expression of these 
genes is lost in the Nurr1 null embryo [147, 149-152]. The Nurr1 pathway appears to 
be distinct from specification as Nurr1 null mice have a correctly specified midbrain 
dopaminergic neural lineage expressing Pitx3 and Aldh1a [153]. Nurr1 directly 
regulates TH expression via activating the NGF1 responsive element in the TH 
promoter region after its own phosphorylation by Erk1/2. [154]. Nurr1 appears to 
have an additional role as these neurons fail to migrate laterally to their normal 
positions during development and were unable to innervate their target tissue [153]. 
Paired-like homeodomain transcription factor 3 (Pitx3) is expressed in midbrain 
dopaminergic neurons in the marginal zone from E11 onwards [155-157], null mice 
show preferential loss of SNc neurons while VTA neurons are affected to a lesser 
extent [158, 159]. Prior to cell death the down regulation of TH in the SNc population 
was observed [159]. As both VTA and SNc express Pitx3 these findings suggests 
that VTA and SNc neurons differ in their molecular make up. The regulation of TH 
via Pitx3 also differs in these populations of neurons, with SNc neurons expressing 
Pitx3 prior to TH, whilst VTA neurons express TH and Pitx3 simultaneously [159]. 
Pitx3 has been shown to bind to the promoter of TH indicating Pitx3 may directly 
regulate TH in vitro [160-162]. However over expression of Pitx3 in hippocampus 
progenitors didn’t cause an increase in TH [163] suggesting that Pitx3 can only have 
an effect in specific cell types, unlike Nurr1 which seems to activate TH expression 
independent of cellular context [164]. Pitx3 null mice are also deficient in Aldh1a and 
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DAT [165]. Aldh1a, a retinoic acid synthesising enzyme, is a SNc specific Pitx3 
target gene and can partially rescue Pitx3 deficient phenotype [166, 167] suggesting 
that Aldh1a acts downstream of Pitx3 in the SNc neurons.  
While both Pitx3 and Nurr1 regulate expression of the known genes involved in 
terminal differentiation, over expression of either of these transcription factors alone 
promotes expression of only a subset of terminal differentiation markers [66, 163, 
164, 167-170]. Co-expression of both Pitx3 and Nurr1 during neuronal differentiation 
of ES cells induces the highest expression of TH, VMAT, DAT and Tuj1 [170]. The 
authors therefore propose that Nurr1 and Pitx3 act synergistically to induce the 
terminal differentiation of midbrain dopaminergic neurons [170].  
As well as triggering expression of dopamine transmission and synthesis machinery, 
terminally differentiated and differentiating neurons require factors for survival. En1/2 
are required for survival of dopaminergic neurons in the late stages of foetal 
development and in adults [171-174]. In En1/2 null mice all midbrain dopaminergic 
neurons die between E12, the onset of En expression, and E14 [171]. The En1+/-
En2-/- mutant has normal midbrain dopaminergic composition at birth but loses TH 
neurons in the SNc whilst retaining those of the VTA [173]. This highlights the 
sensitivity of the SNc neurons which have distinct survival requirements. 
Understanding the developmental cues required for development of this subset of 
neurons is essential for therapeutic approaches for PD and may also improve 
understanding of why the SNc neurons are more vulnerable and preferentially lost in 
PD. In addition to Engrailed genes it is thought that retinoid x receptor–Nurr1 
heterodimers are involved in survival of mature midbrain dopamine neurons [175].  
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Figure 1.4. Putative genetic network involved in ventral midbrain differentiation. Solid 
lines indicate regulation that is direct. To qualify as direct regulation, at least one publication 
has show by Chromatin Immunoprecipitation binding of the specific protein to the promoter. 
Dotted lines are regulations which have not been shown to be direct cis-regulation. The 
information in this network highlights the main players and is inclusive of all published data 
rather than selective. As several genes, such as FoxA2, are involved at several stages of 
this process, the gene is placed at the level where expression first starts, i.e. in the 
potentiation section, however arrows go all the way down to terminal differentiation stage to 
indicate that this gene continues to be expressed in the third layer and has a role in this later 
stage as well. Information was taken from the following publications to create this network. 
[103, 105-107, 114, 115, 117-125, 129, 131, 132, 139, 176-178].  
 
1.3 In vitro midbrain dopaminergic specification  
In vitro specification methods are based on information obtained from in vivo studies. 
Therefore almost all stem cell based dopamine differentiation protocols start by 
addition of Shh and FGF8 which potentiate cells to midbrain dopaminergic fate [65, 
66, 111, 112, 179]. This typically results in 30% of the neuronal population 
expressing Tyrosine Hydroxylase (TH) the rate limiting enzyme for dopamine 
production [180]. However, unless combined with genetic manipulation of midbrain 
dopaminergic transcription factors such as Pitx3, Nurr1 or Lmx1A [66, 115, 159, 170, 
181], the number of neurons with midbrain regional identity generated is low. 
Furthermore, the yield of TH+ neurons is inconsistent between experiments and 
highly variable even within the same culture.   
Another protocol which is even less effective for the generation of TH positive cells 
involves induction of Stromal cell-derived inducing activity (SIDA) [182]. Using this 
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method, only 15% of SIDA ES cells with TH and Dopamine Transporter (DAT) 
expression are also Pitx3 positive [183]. Whilst in vivo all midbrain dopaminergic 
neurons simultaneously express these three markers. In summary, current ES cell 
dopaminergic differentiation protocols produce heterogeneous somatic cell 
populations and of the dopaminergic neuronal cells within the population not all 
exhibit true midbrain identity. 
One of the major limiting factors in efficient generation of midbrain dopaminergic 
neurons from stem cells is the heterogeneity of ES cell-derived neural progenitors. 
Within a given differentiation culture derived from ES cells, progenitors of different 
developmental stages and/or positional identities are present. As a result of these 
differences the specific cells within this mixed cell population respond differently to 
the inductive factors added. 
To improve differentiation methods attempts were made in the Li lab to create a 
more homogenous starting population for in vitro differentiation to dopaminergic fate. 
Epi Stem Cells (EpiSC) are a population of cells which can be obtained from the 
primitive ectoderm/epiblast stage and as such offer a pluripotent but more restricted 
and synchronised population of cells [184-186]. Within our lab we have found that 
EpiSCs convert to neuroectoderm cells more quickly than ESCs when subjected to 
monolayer differentiation. However without further manipulation the total numbers of 
TH+/Pitx3+ cells are still low. 
Further research in the lab based on in vivo experiments identified that inhibition of 
FGF/ERK signalling at the start of neural induction during the monolayer 
differentiation protocol resulted in nearly 40% of TH+ neurons co-expressing Pitx3 
[187]. This improvement may be due to the more synchronous conversion of EpiSC 
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to neuroepithelial fate which allows efficient stimulation of midbrain dopaminergic 
competent progenitors, coupled to the early induction of both Lmx1A and FoxA2 and 
repression of forebrain and hindbrain fates by inhibiting FGF receptor (PD173074) or 
ERK (PD0325901) [187]. These findings are consistent with the developmental role 
of FGF signalling in regionalization of the forebrain [188, 189]. 
This method is based on addition of a small molecule rather than transgene 
manipulation of Lmx1A, Nurr1 or Pitx3. Therefore it provides an approach which is 
more easily applicable to generation of midbrain dopaminergic neurons for 
transplantation and for disease modelling. As this method was the most efficient for 
generation of midbrain dopaminergic neurons in culture, the use of EpiSCs with the 
addition of PD173074, at the point of neural induction, was used in cell culture 
experiments carried out in this thesis.  
 
1.4 Dmrt5 
Genes related to the Drosophila melanogaster Doublesex (dsx) and Caenorhabditis 
elegans Mab-3 are an evolutionary conserved family of transcription factors known 
as the Dmrt (Doublesex and Mab-3 related transcription factor) gene family [190, 
191]. Dmrt family members, are characterised by a DNA binding motif known as the 
DM domain [192], which was first identified in the Drosophila gene dsx [193] and 
later in the  C.elegans gene Mab-3 [192]. All higher metazoan species investigated 
have multiple DM domain proteins: there are 4 in Drosophila, 11 in C.elegans and 7 
in mouse and 8 in humans [191, 194-198]. Outside of the DM domain members of 
the Dmrt family share little sequence similarity even within species. Despite this the 
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role of DM family in regulation of sexual differentiation is well conserved across phyla 
[199, 200]. 
The DM domain is notable not only for its conserved role in regulating sexual 
differentiation, but also for to its unusual structure and mode of action [193, 201]. 
The DM domain is bipartite, comprised of an amino-terminal zinc binding module and 
a more variable carboxy-terminal domain [202, 203]. The structure of the DM domain 
is unrelated to the structure of other zinc finger motifs, consisting of an intertwined 
module coordinating 2 zinc ions [203]. Moreover base substitution experiments 
indicate the DM domain also differs from other zinc fingers in its interaction with DNA 
on the minor, rather than major, groove [204]. Mutational analysis indicates that the 
DM domain interacts with DNA via the zinc binding module and the C-terminal tail 
mediates high affinity DNA recognition by widening the minor groove without bending 
the DNA [205].  
Binding of Dmrt family members to the minor groove is postulated to enable 
simultaneous binding of major groove factors to the same region of the enhancer 
element [206]. The best example of this comes from the enhancer of the yolk protein, 
Yp1, in Drosophila, which contains a binding site for a bZip protein and a Dsx binding 
site. DSX-F cooperates with the bZip protein to activate Yp1 transcription in females, 
while DSX-M is thought to antagonise this protein, helping to ensure that Yp1 is not 
transcribed in males [206]. How this occurs is not known, however DSX-M has a 
larger C-terminal domain than DSX-F which may occlude the binding site of the bZip 
protein. Furthermore, in C.elegans, Mab-3 binding to the Ref-1 promoter is thought 
to repress transcription in part via antagonising activation by an unknown protein that 
binds to an overlapping site [207].  
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In vertebrates and C.elegans, Dmrt genes are thought to bind as dimers to a 
pseudopalindromic DNA site [205]. In support of this, mouse Dmrt3 and mouse 
Dmrt5 in vitro efficiently formed protein DNA complexes that could be supershifted 
[208]. Mouse Dmrt5 is thought to be a transcriptional repressor, as experiments 
carried out in the Li laboratory by Xinsheng Nan show that fusion of a Gal-4 DNA 
binding domain to Dmrt5 represses expression of a UAS Luciferase reporter. An in 
vitro random oligonucleotide selection method to determine the preferred DNA 
binding sites of 6 of the 7 mouse Dmrt proteins (Dmrt 1-5 and Dmrt7) found that all 
these protein select very similar DNA sequences despite differences in the primary 
structure of their DM domains [208]. This indicates that the target specificity of the 
vertebrate Dmrt family is unlikely to be derived exclusively from the innate DNA 
binding specificity. In some cases Dmrt heterodimers bound more efficiently than 
homodimers indicating that heterodimer formation may contribute to transcriptional 
regulation of Dmrt proteins [209]. Like Dsx, mouse Dmrt5 proteins were found to bind 
to DNA with high specificity relative to other minor groove proteins [209, 210]. 
Dmrt5 is a member of the Dmrt A group and as such, along with the DM domain, 
also contains a DMA motif in its C-terminal, which is also found in Dmrt3 and 4, the 
function of this conserved region is unknown [198, 211, 212]. Dmrt5 also contains a 
DMB domain located in the C terminus which is conserved only in the Dmrt5 genes 
of fish and mammals [213] (Figure 1.5). While no function for Dmrt5 has thus far 
been described, the role of DM family members in sex differentiation and 
development has been well described in organisms as phylogenetically divergent as, 
C.elegans, Drosophila, Xenopus, fish, birds and mammals [211, 213, 214]. This is 
unusual as most sex specific developmental regulators appear to be conserved only 
in relatively restricted groups of animals. In addition to a role in sex differentiation 
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and development, Dmrt4 in Xenopus regulates neurogenesis of the olfactory bulb 
[215], and Dmrt2 is a regulator of vertebrate segmentation [216-218] demonstrating 
that the Dmrt proteins also function elsewhere during development. Furthermore the 
expression patterns of Dmrt genes are not restricted to the gonadal tissues [219]. 
The known expression patterns of Dmrt family members will be described in the 
introduction to Chapter 3 which investigates the expression of Dmrt5 in the chicken 
embryo.  
 
Figure 1.5. Schematic presentation of mouse Dmrt5 protein. Conserved DM, DMA and 
DMB domains are indicated. Numbers correspond to amino acid positions. Conserved 
domains were mapped using NCBI conserved domain databank [220]. 
 
1.5 Hypothesis and Thesis Aims 
The Li Laboratory wish to understand midbrain dopaminergic development further 
and improve in vitro generation of these neurons. Therefore a microarray screen to 
identify factors expressed in midbrain dopaminergic progenitors of E12 mice was 
carried out. The screen identified Drosophila doublesex and C elegans Mab-3 
related gene (Dmrt5). Preliminary RNA in situ hybridisation revealed restricted 
expression of Dmrt5 in the ventral midbrain between E10 and E12 (Su Ling Zhao). 
The identification of Dmrt5 from a microarray screen, its localisation to the region 
from which dopaminergic neurons arise and the family's previous role in 
development provide evidence to support the hypothesis that Dmrt5 could be 
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involved in midbrain dopaminergic neuron development. To investigate this further, 
in the following results chapters I characterise the expression of Dmrt5 in the 
developing chicken embryo in chapter 3, I describe the use of in ovo electroporation 
and an inducible EpiSC line to investigate the effect of Dmrt5 over expression on 
neuronal differentiation in chapter 4. I discuss results from a microarray screen 
carried out to identify potential functions of Dmrt5 during neuronal development in 
Chapter 5.  
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Chapter 2.  Materials and Methods 
 
1.1 Materials 
Unless otherwise stated, all analytical grade chemicals were obtained from either 
Sigma or BDH Laboratory Supplies (Merck Ltd). Stock solutions were prepared with 
reverse osmosis purified water and filtered and autoclaved as necessary. Agarose 
for electrophoresis was supplied by Invitrogen. Synthetic oligonucleotides were 
synthesised by SIGMA.  
2.1.1 Solutions 
Phosphate buffered saline (PBS): 
137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4.7H2O, 1.4mM KH2PO4 (pH7.4) 
PBST: 
0.2% (V/V) TRITON X 100 (BDH) in PBS.  
1X TAE: 
0.04mM Tris-acetate, 0.001M Ethylenediaminetetraacetic acid (EDTA) 
20X SSC: 
3M NaCl, 0.3M Tri-Na Citrate  
Lysis buffer: 
10mM Tris (pH8.0), 50mM EDTA, 100mM NaCl, 0.5% sodium dodecyl sulphate 
(SDS), 0.5mg/ml Proteinase K (Roche) added just before use.  
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Luria-Bertani (LB) broth: 
1% (w/v) tryptone (Difco), 0.5% (w/v) yeast extract, 85mM NaCl. 
LB Agar: 
1.5% (w/v) agar (Difco) in LB broth. 
ChIP lysis buffer: 
0.1% Triton X-100, 0.4mM PMSF (SIGMA) in PBS.  
MA buffer: 
0.25M Sucrose, 3mM MgCl2, 10mM Tris-acetate pH8.0. 
ChIP Resuspension buffer: 
4ml MA, 1ml 5x Complete protease inhibitor cocktail (Roche), 2mM CaCl2 
ChIP dilution buffer: 
200mM NaCl, 1mM EDTA, 1%Triton X-100, 20mM Tris-acetate pH8.0. 
ChIP elution buffer: 
0.1M NaHCO3, 1% SDS. 
TBST 
1x TBS and 0.1% Tween 20 
MAB (pH7.5)  
0.1M Maleic acid pH adjusted to 7.5 with NaOH, 0.15 M NaCl 
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MABT 
MAB with 0.1% Tween-20 
Blocking solution 
MABT + 2% Boehringer Blocking reagent (Roche) + 20% FCS 
NTMT 
100mM sodium chloride (BDH), 100mM TrisHCl (Sigma) pH9.5, 50mM magnesium 
chloride (BDH), 0.1% Tween-20 (BDH).  
4% Paraformaldehyde 
17.5 grams paraformaldehyde (BDH), 500ml PBS heated to boiling, drops of 1M 
NaOH added until solution clears to adjust pH. 
PBST  
PBS with 0.1% Tween-20 
Prehybridisation mix (Prehyb) 
50% formamide (Fluka 47670) 
1.3M SSC (use 20X SSC at pH5)  
5mM EDTA 
0.2% Tween-20 
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Hybridisation mix 
Prehyb + 10% (w/v) CHAPS, 100ug/ml Heparin, 50ug/ml Yeast tRNA + 0.1mg/ml 
probe 
 
2.2 Molecular biology methods 
2.2.1 Transformation of competent cells 
50µl aliquots of DH5α competent cells (Invitrogen) were thawed on ice and 
approximately 10ng plasmid DNA was added. Competent cells were gently stirred 
and placed on ice for 30 minutes. The tube was heated at 42oC for 20 seconds and 
immediately placed on ice for 2 minutes. 1ml of LB broth was added and the tube 
was incubated in an automated shaker (Sorvall) for 1 hour at 37oC. 20 - 200µl of the 
culture were plated on LB agar plates with appropriate antibiotic selection and 
incubated at 37oC overnight.  
2.2.2 Amplification of transformed bacterial colonies 
Single colonies from the agar plates were picked using a 200µl plastic pipette tip 
(Star Lab) and transferred to a 15ml Falcon tube (Marathon) containing 3ml LB broth 
with appropriate selection. The culture was incubated in a shaker at 225-250 rpm at 
37oC overnight. The bacterial suspensions were used for mini prep (Qiagen). 
2.2.3 Preparation of Plasmid DNA 
Qiagen mini, midi and maxi-prep kits were used according to manufacturer’s 
instructions to obtain desired quantities of plasmid DNA. For mini prep, 1.5ml of the 
culture was centrifuged at 13000 rpm for 2 minutes and the supernatant was 
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discarded. 150µl of solution 1 was added to the tube and vortexed. To lyse the cells 
150µl solution 2 was added and the tubes were inverted 4-5 times to mix. To 
neutralise the lysate, 250µl of cold solution 3 was added and the tube was inverted 
4-5 times to mix. The sample was then centrifuged at 13000 rpm for 10 minutes and 
the supernatant transferred to a clean tube. To precipitate the DNA, 1ml cold ethanol 
was added and the tube inverted 4-5 times to mix before incubating at -20oC for 30 
minutes to overnight. The samples were then centrifuged at 1300 rpm for 15 minutes 
to pellet the DNA, which was then dissolved in the appropriate volume of dH2O to 
give the required concentration of DNA. Purified DNA was quantified using 
NanoDrop ND-1000 (Labtech). 
2.2.4 Extraction and purification of RNA from chicken embryos and 
cultured cells 
For cultured cells: Culture media was aspirated from cells, cells were washed twice 
with PBS. Cells were lysed using Tri-reagent (0.2ml per 2cm2 well, Sigma). The 
lysate was transferred to a clean 1.5ml Eppendorff tube and vortexed. For chicken 
cells: embryos were collected and dissected as described in the preparation for 
microarray experiments section below. Dissected tissue from 6 embryos was put into 
one Eppendorff tube containing 0.5ml tri-reagent (Sigma). The tissue and tri-reagent 
were then vortexed to ensure all cells within the tissue lysed.  
To extract RNA, 200µl chloroform was added and the vortexed for 15 seconds. The 
aqueous phase was collected and 500µl isopropanol added to this to precipitate the 
DNA. The tubes were incubated at room temperature for 30 minutes. Tubes were 
centrifuged at 12000 rpm for 10 minutes at 4oC and the suspension removed. 1ml 
75% ethanol was added to the pellet, and the tube was again centrifuged at 12000 
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rpm for 5 minutes. The supernatant was removed and pellet air-dried until clear. The 
pellet was then dissolved in required volume of RNase-free water. Purified RNA was 
quantified using NanoDrop ND-1000 (Labtech). 
2.2.5 Reverse transcription 
To generate cDNA from purified RNA, 1µg total RNA was mixed with 1µl Random 
Primers (3µg/µl, Invitrogen), 1µl dNTP mix (10mM, Invitrogen) and the appropriate 
volume of water to give a total volume of 13µl in  a thin walled PCR tube (Fisher). 
The tubes were placed in a PCR machine and the following program was executed. 
5 minutes at 65oC 
1 minute at 4oC 
Samples were removed from the PCR machine and 4µl 5x first strand buffer 
(Invitrogen), 1µl 0.1M DTT, 1µl RNAguard RNase inhibitor (27600U/ml, Amersham 
Bioscience) and 2µl Superscript III reverse transcriptase (200U/µl, Invitrogen) was 
added to each tube.  
5 minutes 25oC 
60 minutes 55oC 
15 minutes 70oC.  
To remove the remaining RNA, 1µl RNase H (2U/µl, Invitrogen) was added and the 
tube was incubated at 37oC for 20 minutes. The cDNA was diluted 1:10 in water 
before being used for quantitative polymerase chain reaction (Q-PCR).  
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2.2.6 Real-time PCR 
For Real-time PCR 2µl of cDNA was mixed with 10µl MESA Green qPCR Mastermix 
Plus mix (Bio-Rad), 10mM each of the forward primer and reverse primer and 6µl 
water. Amplification was done for 40 cycles (94oC 1min, 65oC 1min, 72oC 1min). Q-
PCR was carried out using the Chromo 4 real-time PCR system (Bio-Rad).To verify 
the PCR product, melting curves were carried out in each reaction. Real-time PCR 
was performed in triplicates.  
2.2.6.1 List of Q-PCR primers  
Chick gene 
primers 
  Genes Forward Reverse 
GFP  ACGTAAACGGCCACAAGTTC AAGTCGTGCTGCTTCATGTG 
Beta actin CACCATTGGCAATGAGAGG GATTCATCGTACTCCTGCTTGC 
18s RNA GACACGGACAGGATTGACAG GACAAATCGCTCCACCAAC 
GAPDH GAAAGGTCGCCTGGTGGATC GGTGAGGACAAGCAGTGAGGAACG 
Hes1 AAAGACAGCTCTCGGCACTC CCTCGTTCATGCACTCATTG 
Meis 2 CTCCTTCGACTCCTTCAACG ACCGATGGCAGAAGTTATCG 
Cald1 ACGGTTTAGCATCGACACTCC ATGGAAGTGTTGAACGGGAG 
GDPD5 TCCTCATCCTCACCTCATCC AGGTTCATTTGCTGTCCCAC 
arghef9 GGAGCGTTATCGCAAAGAAG TGGTAAGTGGGTTCCTCCTG 
Meis2 CTCCTTCGACTCCTTCAACG ACCGATGGCAGAAGTTATCG 
cxcl12 CAACTGCTCGCTTCAGATTG TGGATCCATTTTAGCTTGGG 
Cadm1 CAACATGCCGTACTGTCTGG CCTGCTCGAGAATCGTATACATACAGC 
Itgb5 TATGAAATGGCCTCAAACCC TGTTGAACTTGTTGAAGGCG 
Hes1 AAAGACAGCTCTCGGCACTC CCTCGTTCATGCACTCATTG 
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Mouse 
gene 
primers 
Forward Reverse 
Dmrt5 GCCTGCCTACGAAGTCTTTGGCTCGG
TTT 
CGTCTTGGGAAACAGATCAAACTTCTGCA
ATTT 
HMBS ACTGGTGGAGTCTGGAGTCTAGATG
GC 
GCCAGGCTGATGCCCAGGTT 
Cyclophilin GGCAAATGCTGGACCAAACAC TTCCTGGACCCAAAACGCTC 
GAPDH GACCACAGTCCATGCCATCACT TCCACCACCCTGTTGCTGTAG 
Hes1 TCGGTGGGTCCTAACGCAGT ACGGGTAGCAGTGGCCTGAG 
Ngn2 GCTGTGGGAATTTCACCTGT AAATTTCCACGCTTGCATTC 
Mash1 CCCTGAAACTGGGTTGATGT AAAGGCTGTCCGAGAACTG 
Nato3 TCTGCGAGTTCCCACCTGGGG TTTTGGGGCGGCCCAGCAAG 
Cyclin D1 TTTCTCTGCCCGGCTTTGATCTC CGCGCGGAGTCTGTAGCTCTC 
PCNA TTCGCTGCCGCTTCTGCATCG TTGCGGTCGCAGCGGTATGTG 
p21 GCAGCCGAGAGGTGTGAGCCG ACGCGCTCCCAGACGAAGTTG 
p27 ACAAGCGGAGCACCCCAAGC GCAAGCTGCCCCTCTCCACC 
chk1 GGCTTGGCAACGGTATTTCGGC TCACTGGGCTGGTCCCACGG 
chk2 TCGGTGACCCTCCCTGTGGC GCCCCACACACAGACAGGCG 
wee1 AGCCGCGGAACCCGAACTTG GGCGGAGCACGGGAGAACAC 
Socs3 CCAGCCTGCGCCTCAAGACC GCGTGCTTCGGGGGTCACTC 
 
 
2.3 Chromatin Immunoprecipitation 
2.3.1 Preparation and fragmentation of chromatin  
Approximately 1x107 cultured cells were cross-linked with 1% formaldehyde for 10 
minutes at room temperature. 20ml Chromatin Immunoprecipitation (ChIP) lysis 
buffer was added and cells were removed from petri dish by scraping and transferred 
to a 50ml Falcon tube (BD Biosciences), cells were then centrifuged in Eppendorff 
5810R centrifuge, at 2000 rpm for 5 minutes at 4oC. The suspension was discarded 
and the pellet resuspended in 500µl ChIP Resuspension buffer. To fragment the 
chromatin, 0.5µl micrococcal nuclease (100U/ml, Roche) was added and tube was 
incubated at room temperature for 5 minutes. 25µl EDTA, 25µl 20% Triton X-100 
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and 25µl 20% SDS were added and the mixture sonicated with Sonics sonicator 
(Vibra Cell) for 2 minutes. The lysate was centrifuged at 12000 rpm for 15 minutes at 
4 oC and DNA suspension transferred to a clean 1.5ml Eppendorff tube.  
2.3.1.1 Testing chromatin fragmentation. 
1µl RNAase A (10mg/ml, Invitrogen) was added to 50µl DNA suspension, this was 
then incubated for 10 minutes at room temperature. 450µl ChIP elution buffer and 
20µl 5M NaCl were added and samples were incubated at 50oC overnight. DNA was 
purified by addition of 500µl phenol/chloroform (1:1 v/v). The tubes were mixed and 
centrifuged at 12000 rpm for 5 minutes at room temperature. The aqueous phase 
was transferred to a clean eppendorff tube, 50µl 3M NaOAc and 500µl isopropanol 
were added and samples were incubated at -20 oC for 1 hour. The tube was 
centrifuged at 12000rpm for 15 minutes at 4 oC. The resulting pellet was washed with 
1ml 75% ethanol and resuspended in 50µl TAE. To check DNA fragmentation, 5µl 
DNA was loaded onto a 1.5% agarose gel which was run at 90V for 1 hour. To 
assess the concentration of DNA in each sample NanoDrop was used.  
2.3.2 Immunoprecipitation of fragmented chromatin 
Chromatin samples were diluted so the concentration of all samples was the same 
using the required volume of ChIP resuspension buffer. 4.5ml ChIP dilution buffer 
and 500µl DNA suspension were added to a 15ml Falcon tube (BD Biosciences), 
samples were incubated on ice for 5 minutes. Samples were centrifuged at 12000 
rpm for 15 minutes at 4 oC. 1ml supernatant (cleared chromatin); 40µl salmon sperm 
DNA/protein A agarose (SIGMA) and desired volume of antibodies were added to a 
clean 1.5ml eppendorff tube. Tubes were incubated overnight at 4 oC on a rotating 
wheel, and then centrifuged at 800rpm for 1 minute at room temperature. Following 
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careful removal of the supernatant agarose beads were washed 3 times with 1ml 
ChIP dilution buffer and two times in TAE. To elute DNA from the agarose beads, 
500µl ChIP elution buffer was added to each sample. The samples were then 
incubated for 15 minutes at room temperature and then centrifuged at 800rpm for 1 
minute. 20µl 5M NaCl was added to the samples which were then incubated 
overnight at 50 oC. The DNA was purified as set out in the previous section. The 
DNA was used for Real-time PCR.  
 
2.3.2.1 List of antibodies used in ChIP experiments 
Antibodies Amount for ChIP 
Histone H3 (ab1791, Abcam) 2µl 
Trimethyl Lys 4 histone H3 (ab12209, 
Abcam) 10µl 
Trimethyl Lys 27 histone H3 (07-449, 
Upstate) 5µl 
Dmrt5 (custom made) 20µl 
Non specific antibody (serum lab) 20ul 
 
2.3.2.2 List of Primers used in Q-PCR analysis of ChIP experiments.  
Primers Forward Reverse 
p-2 AGGACATCAGGTTCTGTGCC AGATTCCCCACAAGATTCCC 
p0 ACATACAGAGTTCGAGCGGG TTCTCTGGGCTTTGCTTAG 
p2b CGTGTCTCTTCCTCCCATTG ATTCCGCTGTTATCAGCACC 
p4 CCACCTCTCTCTTCTGACGG AGGCGCAATCCAATATGAAC 
 
2.4 Mammalian cell culture 
Cells were grown in tissue culture plastics (Nunc) coated with 0.1% gelatine 
(SIGMA) and incubated at 37 oC with 5% CO2 in a humidified incubator (Sanyo). All 
solutions were sterility tested before use. To avoid bacterial and fungal 
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contamination, all tissue culture manipulations were carried out inside a laminar flow 
sterile hood (Nuaire) and surfaces and objects were sprayed with 70% ethanol 
before used.  
2.4.1 EpiSC medium 
100 mL Neurobasal Medium (Invitrogen, 21103) 
100 mL DMEM/F12 (Invitrogen, 21331) 
2 mL50x B27 (without vitamin A; Invitrogen, 12587-010) 
1 mL100x N2 (Invitrogen, 17502-048) 
200 μL 2-Mercaptoethanol (Invitrogen, 31350-010) 
2 mL L-Glutamine(with penicillin/streptomycin;Invitrogen, 10378) 
 
Add to EpiSC media before putting media on cells: 
10 μg/mL FGF2 (Peprotech, 110-18b) 
25 μg/mL Activin A (R&D, 338-AC-025) 
 
2.4.2 Coating Plates 
For passaging, 6-well plates were incubated with1ml FCS at 37°C for at least 1 hour. 
Before use, wells were rinsed twice with PBS. For EpiSC differentiation plates were 
coated with fibronectin (15 μg/mL) and incubated at 37°C for at least 1 hour. 
Fibronectin was aspirated off before plating cells.  
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2.4.3 Passaging 
Cells were passaged once they reached ~80% confluency (or before they start to 
grow in 3D structures). Media was removed from the plate and cells were rinsed with 
PBS. For a well of a 6 well plate, 1 mL PBS was added per well and left for a few 
minutes until the cells started to round up. PBS was aspirated off, and 1 mL EpiSC 
media was added to the well. The bottom of the well was scratched with 5 mL 
pipette, back/forth in all directions to loosen as many cells as possible off of the 
bottom of the well. This method helps the cells remain in clumps, as they grow best 
this way in culture, rather than as single cells. Cell-media suspension was then 
triturated gently three times. Cells were then plated at three different densities.  6-
well plate pre-treated with either FCS or fibronectin have 3 mL EpiSC medium added 
to each well. To each well containing 3mL EpiSC media,100, 200 or 300ul of the 
1mL cell-media suspension was added.  
 
2.4.4 Neural Differentiation 
Once EpiSCs reach ~50-60% confluency, aspirate EpiSC media, rinse 1x (with 
N2B27 media) and add 3 mL N2B27 +PD (PD0325901, 1 M, Axon), to each well. 
Cultures are split at day 2 in the following manner: Rinse 1x with PBS, add PBS and 
let sit for a few minutes, aspirate, and add 1 mL N2B27 media. Scratch with a 5 mL 
pipette and transfer cells to a new 6 well plate pre-coated with fibronectin. Plate cells 
at 6 different densities depending on how dense you would like them. Typically, add 
3 mL N2B27 to each well of a 6 well plate first, then add 200, 150, 100, 75, 50, 25 μL 
cells per well. After splitting, change media when needed (usually every other day).  
At day 5, 100ng/mL doxycycline was added to half the DA2-5 cultures to induced 
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exogenous Dmrt5 expression. Doxycycline was also added to half the tetracycline 
reverse transcriptional activator (rtTA) cultures as a control. Cells are then collected 
on day 6 or 7. Neurons appear between days 4-8.  
2.5 Animal analysis 
Fertilized chicken eggs were incubated at 37 oC for desired period of time to obtain 
the required stage of embryo.  
2.5.1 In ovo electroporation 
Hamburger-Hamilton (HH) st10 embryos were windowed and electrodes placed at 
either side of the developing head (CUY610P1.5-1, Sonidel Ltd.) [221].  A solution 
containing 7µg/µl DNA construct pcaβ-IRES-GFP, or pcaβ-Hes1-IRES-GFP or pcaβ-
Dmrt5-IRES-GFP, 2% Polyvinyl alcohol, 0.05% Fast Green in water was injected into 
the developing midbrain. 5 x 12 volt square wave pulses of 50ms duration with an 
interval of 100ms were applied across the electrodes using an ECM830 Electro-S 
Square Porator (BTX lnc.). Following exposure to current, embryos were incubated 
at 37oC for 24 hours; embryos were collected at the required stage. The procedure is 
depicted in Figure 2.1. 
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Figure 2.1. In ovo electroporation. A. Fertilised egg was incubated until it reached the 
required developmental stage. Egg is then windowed to visualise embryo. Electrodes are 
placed either side of developing anterior neural tube. DNA is injected into this region and a 
series of square wave electrical pulses are applied across the electrodes such that the DNA 
is taken up by cells adjacent to the positive electrode. B.  HH st 16 embryos which were 
electroporated with pcaβ-Dmrt5-IRES-GFP 24 hours earlier. In situ for exogenous Dmrt5 
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(using mouse Dmrt5 probe) has been carried out on the embryos, as can be seen the over 
expression is only on one side of the embryo. 
 
2.5.2 Whole mount in situ hybridisation 
Embryos were removed from eggs at desired stage, put into PBS or tyrodes solution 
and embryonic membranes removed. Cavities were opened; embryos were then 
fixed in 1-4% PFA for 1 hour-overnight depending on developmental stage. For this 
procedure unless otherwise stated, washes were carried out at room temperature 
and on rollers. Embryos were washed twice in PBST for 5 minutes, and then 
dehydrated through 25%, 50%, 75% MeOH/PBST and 100% MeOH. Solutions were 
changed when embryos sank to bottom of the tubes. Embryos were then bleached in 
6% H2O2/MeOH for 15 minutes up to 1 hour depending on stage.  Embryos were 
then placed in 100% methanol (MeOH) and stored at -20 oC overnight or until 
needed. To start in situ, embryos were rehydrated through methanol in the reverse 
order to PBST. Solutions were changed when embryos sank. Embryos were then 
washed in PBST for 5 minutes twice and placed in a solution of PBST containing 
between 10µg/ml – 1µg/ml Proteinase K (Roche) in PBST. Embryos were left in this 
solution without shaking for between 10-20 minutes depending on stage. Embryos 
were then placed in 4% PFA + 0.1% glutaradehyde (Roche) for 20 minutes. After this 
post fix embryos were washed in PBST twice for 5 minutes, and then rinsed in a 1:1 
mixture of PBST/Prehybridisation buffer. The solution was changed and embryos 
were then incubated at 70 oC in prehybridsation buffer (prehyb) overnight. The next 
evening the embryos were placed in prewarmed hybridisation buffer containing 
approximately 1µg/ml probe. The following day embryos were rinsed in prehyb at 70 
oC twice and then washed in Prehyb buffer at 70 oC for 20 minutes twice, during the 
second wash embryos were taken out of the 70 oC incubator and allowed to cool to 
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room temperature. Four 5 minute washes with MABT were carried out followed by 
two 30 minute washes with MABT. Embryos were then blocked with 2% BBR , 20% 
FCS in MABT for 1-2 hours at 4 oC, followed by incubation with Anti-DIG (1:2000, 
Roche) in 2% BBR 20% FCS in MABT overnight at 4 oC on a rocker. The next day 
embryos were rinsed in MABT for 5 minutes, four times followed by five 1 hour 
washes in MABT before being left overnight in MABT. The following day embryos 
were washed in NTMT twice for 10 minutes, they were then placed in colour reaction 
(3.5µl BCIP and 4.5µlNBT per 1ml NTMT), and at this point embryos were kept in 
the dark. Colour reaction was changed when solution turned purple or when 
embryos were sufficiently stained.  Embryos were washed in NTMT for 10 minutes 
and then washed in MABT for 10 minutes or longer to reduce background. Embryos 
were then stored in PBST short term or 4% PFA for long term storage.  
 
2.5.3 In situ hybridisation on sections 
Frozen sections were allowed to equilibrate to room temperature.  Labelled probe 
was diluted 1:1000 in hybridisation buffer and at least 300µl was placed on each 
slide. A coverslip was laid over this solution, and sections were incubated at 65 oC in 
a humidified chamber overnight. After hybridisation, coverslips were removed and 
sections rinsed twice in MABT for 5 minutes each. Sections were then washed in 
wash buffer at 65 oC for 30 minutes twice, followed by two 5 minute washes with 
MABT. Sections were then blocked with blocking solution for 1 hour. AP-Anti-Dig 
antibody was diluted at 1:500 in blocking solution and 500µl of this solution was 
added to each slide. Sections were incubated overnight at 4oC in a humidified 
chamber. Sections were washed for three times in MABT for 10 minutes each. 
Sections were then washed in pre-development buffer for 2 minutes. Slides were 
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incubated at 37 oC in development buffer pH9.8, 5% PVA containing NBT and BCIP 
until sections acquired required intensity of blue colour. Reaction was stopped by 
washing slides in tap water. The sections were dried and mounted using a xylene 
based mounting solution. Sections were stored in the dark.  
2.5.4 Cryostat sectioning 
Embryos were dissected in tyrodes solution, and then fixed in 1-4% PFA in PBS for 1 
hour. The embryos were then cryoprotected in 30% sucrose in PBS which was left at 
4oC until embryos sank. Embryos were then embedded in OCT (BDH) in embedding 
boxes or foil parcels over dry ice and stored at -80oC until use. Cryosectioning was 
performed at -18 to -21oC  and cryostat and sections were cut at 100-5 µm. Sections 
were collected on polylysine slides and dried at room temperature for 30 minutes 
and then either used immediately for in situ or immunostaining or stored at -80oC  
until use.  
2.5.5 Immunohistochemistry 
Frozen sections were allowed to equilibrate to room temperature. Sections were 
blocked with serum in PBST for 1 hour at room temperature and were then 
incubated with primary antibodies in blocking solution at 4oC overnight in a 
humidified box. Sections were washed three times for 20 minutes with PBST at room 
temperature, then incubated with horseradish peroxidise (HRP) or fluorescence – 
conjugated secondary antibodies either at room temperature for 1 hour or overnight 
at 4oC. Sections were then washed three times in PBS. For DAPI staining, sections 
were then incubated with DAPI (1:5000) for 3 minutes and washed three times in 
PBS. Sections were then mounted using Vector mount (Dabco) and analysed using 
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a Leica TCS SP5 confocal microscope equipped with 405 Diode, Argon, HeNe 594 
and HeNe 633 lasers.  
2.5.5.1 Primary antibodies used 
 
Antibody Host Supplier Concentration Block  
PH3 Rabbit Abcam ab 32107 1 in 500 
2% BSA 5% Serum 0.2% Triton X-
100 
DAPI 
dilactate 
 
Invitrogen D3571 2mg/ml PBS 
Tuj1 Rabbit 
Covance PRB-
435P 1 in 1000 
2% BSA 5% Serum 0.2% Triton X-
100 
 
2.5.5.2 Secondary antibodies used 
Flurophore Antigen Host Supplier Concentration 
Alexa 488 Mouse IgG Donkey Invitrogen 1 in 200 
Alexa488 Rabbit IgG Donkey Invitrogen 1 in 200 
Alexa 594 Mouse IgG Donkey Invitrogen 1 in 200 
Alexa 594  Rabbit IgG Donkey Invitrogen 1 in 200 
 
2.5.6 Tissue preparation for microarray analysis and real-time PCR 
 
Embryos were collected and washed in tyrodes, and were transferred to clean 
tyrodes for dissection of the midbrain region. Dissected tissue was then treated with 
2U/ml dispase (SIGMA) for 10-15 minutes. Mechanical dissection was used to 
remove the neural tube from the mesoderm. Ventral lateral midbrain (VLM) was 
dissected from wild type embryos without any treatment (VLM), embryos which had 
experienced electric current (VLMi), embryos exposed to current and GFP (VLMg) 
and embryos exposed to current and regulatory gene Dmrt5 (VLMd). Tissue for real-
time PCR of electroporated embryos was obtained by the same method. 
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2.5.7 Microarray  
For each microarray 6 independent tissue samples of  VLM,  VLMi,  VLMg or VLMd 
were collected and pooled. Total RNA was isolated from each pool using the 
Absolutely RNA Miniprep Kit (Stratagene).  RNA was sent to UK Bioinformatics for 
processing and analysis. The procedure used was as follows: cDNA was biotin 
labelled. Samples were hybridized to GeneChip Chicken Genome Array (Affymetrix) 
according to manufacturer’s protocol. For each condition three sets of pooled 
samples were collected and hybridised to three arrays Chicken Genome Arrays 
(Affymetrix) to obtain three biological replicates for each condition. Following Mas5, 
normalisation and filtering, genes whose expression differed significantly between 
control condition VLM and experimental conditions: VLMi, VLMg or VLMd were 
identified by one-way ANOVA and SNK post hoc test as outlined below.  
2.5.8 Bioinformatics 
Probe levels were calculated from raw data using Mas5 algorithm embedded into the 
GCOS suite (version 1.2; Affymetrix). Data were analysed using GeneSpring 
package (version GX11; Agilent Technologies, Wokingham, Berkshire, UK). The 
suitability of the expression data sets for inclusion in the analysis and the overall 
relationship between biological replicates was assessed using quantile plots and 
principle component analysis. Samples were first normalised to the 50th percentile 
(median) across the entire expression data set. Genes were then filtered to remove 
any genes absent in all arrays. To identify genes showing differential expression 
between the three samples a one-way ANOVA and SNK post hoc test with no 
Multiple Testing Correction was carried out. A p-value of < 0.05 and a ≥ 1.5 fold 
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change in gene expression was used to determine genes showing differential 
expression between the samples. 
 
 
2.5.9 Ingenuity network analysis 
The differentially expressed genes were used to perform network analysis using 
Ingenuity Pathways Analysis v8.0-2602 (IPA) (http://www.ingenuity.com). The 
Ingenuity Knowledge Base is the largest knowledge base of its kind, with millions of 
findings curated from the full text literature. For analysis, the Affymetrix Chicken 
Genome Array gene list was used as a reference set. All data sources, all species, 
and all neuronal tissues and neuronal cell lines were used for the analysis. IPA uses 
a Fisher's exact test to determine which pathways are significantly enriched within 
the set of genes showing differential expression compared to the entire list of genes 
represented on the array. 
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Chapter 3. Expression of Dmrt5 in Chicken embryos 
 
3.1 Introduction 
Dmrt5 is a member of the Doublesex and Mab-3 related transcription factor family. 
Dmrt family members contain a non-classical zinc finger like DNA binding motif 
known as the DM domain [222]. The DM domain is broadly conserved among 
metazoan family members [203]. This family of proteins has been shown to regulate 
sexual development in arthropods, nematodes and vertebrates [199, 200].  
Although most investigations regarding the function of Dmrt genes have 
concentrated on sexual development [195, 198, 223], the presence of Dmrt gene 
expression in non-gonadal tissue [212, 219] presents the possibility of a role for Dmrt 
genes in development of other tissue types. Many members of the Dmrt gene family 
are expressed in the central nervous system (CNS) of mouse [195, 224], chick [224], 
Xenopus [225] and fish [211]. Dmrt genes have also been identified in the nasal 
placodes [211, 224], the presomitic mesoderm and newly formed somites [218, 226]. 
Whilst expression has been described in various tissues, the functional role of Dmrt 
genes outside of the gonads has remained largely un-investigated with some notable 
exceptions; Xenopus Dmrt4 has been shown to be an important regulator of 
neurogenesis in the olfactory system [225], whilst Dmrt2 is a critical regulator of 
vertebrate segmentation [217].  
As described in Chapter 1, expression of Dmrt5 in the ventral midbrain was detected 
in the Li Laboratory in a microarray experiment designed to find genes expressed in 
ventral midbrain dopaminergic neuron progenitors but not the more lateral tissue of 
E12 mice. In agreement with this finding, expression of Dmrt5 has been observed in 
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the midbrain of Platyfish [211] and Zebrafish [227] and expression of Dmrt5 has 
been observed in the brains of mice [195] and Fugu [223]. Table 3.1 provides full 
details of all published Dmrt5 expression data. 
 
 
Table 3.1. Published data describing Dmrt5 expression during development. Table 
details species in which expression was detected, location of expression, method of 
detection and paper this work was published in. ISH = In situ Hybridisation. 
 
Species Location Detection 
Method 
Citation 
Human Testis PCR Ottolenghi et al., 
2002 [198] 
Mouse Ovary, Testis, brain, 
kidney, heart, lung, 
stomach, adult 
testis 
PCR Kim et al., 2003 
[195] 
Mouse Brain,  ISH Kim et al., 2003 
[195] 
Platyfish Nasal placode, lens, 
forebrain, midbrain, 
olfactory placode 
ISH Veith et al., 2006 
[211] 
 
Zebrafish Ovary, Testis, 
midbrain, midbrain-
hindbrain boundary 
ISH Guo et al., 2004 
[212] 
 
Fugu Eye, brain, heart, 
spleen 
Southern blot Yamaguchi et al., 
2006  [223] 
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To further characterise the expression pattern of Dmrt5, in situ hybridisation using a 
probe for Chicken Dmrt5 was carried out in chicken embryos. We focused on 
describing the expression pattern of Dmrt5 in the ventral midbrain as this region 
gives rise to midbrain dopaminergic neurons of the SNc and VTA [228]. 
 
3.2 Results 
To determine if Dmrt5 is involved in midbrain dopaminergic neuron development and 
specifically in which process of midbrain dopaminergic neuron development the gene 
may have a function in situ hybridisation was used to locate Dmrt5 RNA during the 
time at which midbrain dopaminergic neuron development occurs in chicken 
midbrain. To investigate the expression of chick Dmrt5 by in situ hybridisation, a 
probe was made from an expressed sequence tag (EST) identified in a large scale 
EST project [229], which by Blast analysis showed a 99% identity and 98% coverage 
of the chicken predicted Dmrt5 mRNA (XR 026801.1). This EST was annotated as 
Chicken EST (ChEST) ChEST 44n20 and is a 767 nucleotide sequence.  
Dmrt5 expression was detected in embryos from HH st 16 (equivalent to mouse 
E9.5), when specification to dopaminergic fate first occurs, up until HH st 34 
(equivalent to an E14 mouse), when the majority of midbrain dopaminergic neurons 
have terminally differentiated. This time period covers the entire midbrain 
dopaminergic developmental process from specification, to neurogenesis and 
terminal differentiation. Analysis of whole mount chicken heads sagitally dissected 
show that in the chick, Dmrt5 expression first occurs in the ventral midbrain at HH 
stage 16 at the ventral base of the Zona Limitans Intrathalamica (Figure 3.1). The 
expression of Dmrt5 expands from this anterior position posteriorly from HH stage 16 
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to 34, with expression at its most posterior reaching the isthmus. Thus Dmrt5 
expression is seen in the region which gives rise to midbrain dopaminergic neurons 
during the time at which these neurons are born. Expression of Dmrt5 is also seen in 
the dorsal telencephalon at HH st 16 up until at least HH st 34. (Figure3.1)                   
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Figure 3.1. Expression pattern of Dmrt5 in developing chicken HH st 16 - 34. In situ 
hybridisation for Dmrt5 during development, embryos have been dissected sagitally 
orientated with forebrain on left and hindbrain on right. Arrow indicates midbrain-hindbrain 
boundary with midbrain to the left of the arrow and hindbrain to the right of the arrow. F 
shows forebrain region, M midbrain region and H hindbrain region.  
Having identified expression of Dmrt5 in the ventral midbrain during the development 
of midbrain dopaminergic neurons, I wanted to determine which layer of the 
developing ventral midbrain Dmrt5 was expressed in. As described in Chapter 1, 
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during development the neural tube transforms from a single cell layer of neural 
epithelium into three layers. Each of the three layers contains cells in a different 
stage of midbrain dopaminergic development. By locating the cells that express 
Dmrt5 we may be able to infer what possible role Dmrt5 could have during 
development of midbrain dopaminergic neurons and develop a suitable hypothesis to 
investigate the function of this gene further. 
The three layers of the developing ventral midbrain are shown in Figure 3.2. They 
are the ventricular zone (VZ), which contains the proliferating progenitor pool [106, 
107] and is the region where genes involved in specification are first expressed 
[115]; the intermediate zone (IZ), where cells begin to undergo neurogenesis and 
exit the cell cycle [114, 117]; and the marginal zone (MZ), where the fully 
differentiated neurons expressing TH and Pitx3 along with neuronal marker Tuj1 are 
located [141]. Coronal sections of HH stage 16 - 34 chicken embryos show Dmrt5 
RNA is present in the ventricular zone of the floor plate and a region of tissue 
immediately adjacent to the floor plate within the ventral midbrain throughout 
dopaminergic neuron development (Figure 3.2). While the in situ hybridisation 
images clearly show that Dmrt5 is expressed in the ventral midbrain it would be 
useful to use other probes such as corin and Lmx1A which mark the floor plate and 
Nkx6.1 which mark the more lateral fate, to obtain a more detailed understanding of 
the lateral limits of Dmrt5 expression. 
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Figure 3.2. Coronal sections showing expression of Dmrt5 in the ventral midbrain of 
chicken embryos HH st 16 - 34. In situ hybridisation of Dmrt5 on coronal midbrain sections 
of chicken embryos, 3rd section is a sagital coronal. The three layers of the developing 
ventral midbrain are marked by a dotted line VZ = Ventricular Zone, IZ = Intermediate Zone, 
MZ = Marginal Zone. Zones are defined based on cell morphology. In situ experiments were 
carried out on at least 10 embryos per stage. 
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The RNA expression pattern of Dmrt5 seen in the chicken embryo closely 
recapitulates the protein and RNA expression pattern of Dmrt5 seen during mouse 
midbrain development [230] (Emily Gale, unpublished data). This concurs with the 
high conservation of the Dmrt5 coding regions between mouse and chicken, which 
when compared by Blast show a 71% amino acid (AA) similarity (66% AA identity). 
Indeed Dmrt5 is one of the most conserved of the Dmrt gene family, with platyfish 
Dmrt5 showing 82% AA identity (88% similarity) with Zebrafish Dmrt5 and 57% AA 
identity (88% similarity) with human Dmrt5 [211]. A Dmrt5 homolog (AAA93409) is 
even found in C.elegans [227]. The conservation of Dmrt5 across 46 vertebrate 
species using UCSC genome browser was carried out (Figure3.3).  This analysis 
was done by analysing base-wise conservation using a phylogenetic model, phyloP, 
from the PHAST package [231]. This program  identifies sites predicted to be 
conserved which are assigned positive scores (shown in blue) while sites predicted 
to be fast evolving are assigned negative scores (shown in red), the absolute values 
of the score represent –log p-values and are relative to a null hypothesis of neutral 
evolution. The 46 vertebrate species used for analysis come from the reptile, 
amphibian, bird and fish clades as well as marsupial, monotreme (platypus) and 
placental mammals.  As can be seen in Figure 3.3B the exons of Dmrt5 are highly 
conserved across the 46 vertebrate species. 
In Figure 3.3C the individual alignment of chosen species compared to the human 
Dmrt5 gene can be seen with conserved regions shown in green. This conservation 
was calculated on UCSC genome browser using multiz alignment, a software 
program from the UCSC/Penn state bioinformatics comparative genomics alignment 
pipeline [232]. This analysis shows high conservation in the coding regions of human 
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Dmrt5 when compared to diverse range of the vertebrate family species from 
Monkey, through to Xenopus, Fugu and Zebrafish.  
 
 
Figure 3.3. Conservation of Dmrt5 between species. Image created using UCSC genome 
browser showing A. Dmrt5 human gene B. The conservation of this gene between 46 
vertebrate species, conservation is shown in blue and fast evolving regions shown in red. 
This was calculated using PhyloP which computes the conservation or acceleration p-values 
based on alignment and a model of neutral evolution. C. In green, the conservation between 
Human Dmrt5 gene and several vertebrate species, this was done using multiz alignment on 
the UCSC genome browser. 
 
Outside of the midbrain, Dmrt5 is expressed in the dorsal telencephalon (Figure 
3.4A, C, D) which goes on to form the cerebral cortex, an area of the brain involved 
in memory, attention, perceptual awareness, thought, language and consciousness 
[233]. Dmrt5 is also expressed in the developing eye which forms from the 
evagination of the diencephalon to give rise to optic vesicles [234]. Signalling 
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between this neural tissue and the overlying epithelial tissue leads to formation of the 
eye [235]. During eye development Dmrt5 is expressed in the lens placode, a 
thickening of surface ectoderm which comes into contact with the optic vesicle. This 
lens placode has a role in formation of the optic cup [236] and gives rise to the lens 
and cornea [237-239]. Later in development, expression of Dmrt5 is detected in the 
anterior region of the lens, and is expressed in the overlying epithelium which in 
combination with the migrating neural crest derived mesenchyme cells gives rise to 
the cornea [239]. The cells in the optic stalk also express Dmrt5, this expression is 
first detected at HH st16 and expression is still present in this region at HH st 34 
(Figure 3.4A and B). The optic stalk is the proximal part of the optic vesicle, the 
ventral half of this invaginates and differentiates into glial cells and forms the tissue 
through which projecting retinal ganglion cell axons project, the dorsal half of the 
optic stalk gives rise to non neural tissue that encase the optic nerve [234] . Figure 
3.4C shows expression of Dmrt5 in the nasal placodes which later forms the 
olfactory epithelium of the nose [240] (Figure 3.4C). Dmrt5 expression is also 
present in Rathke’s pouch, which forms part of the pituitary gland a part of the 
endocrine system [241] (data not shown). 
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Figure 3.4. In situ hybridisation showing expression of Dmrt5 outside of the ventral 
midbrain. A. HH st 28 embryo whole mount, Dmrt5 expression in dorsal telencephalon (grey 
arrow) and optic stalk (green arrow) B. HH st 18 coronal section showing Dmrt5 expression 
in optic stalk. C. HH st 16 embryo, dorsal view, showing Dmrt5 expression in lens placode 
(purple arrow), nasal placode (black arrow) and dorsal telencephalon (red arrow). D. HH st 
20 embryo, coronal section of telencephalon showing expression of Dmrt5 in the dorsal 
telencephalon. E. HH st 20 coronal section of eye, Dmrt5 is expressed in the mesodermal 
tissue overlying the optic cup and in the anterior lens.  
B A 
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3.1 Discussion 
Dmrt5 is expressed in the ventricular zone of the ventral midbrain in a tightly spatially 
and temporally restricted manner from HH st 16 until at least HH st 34. As 
dopaminergic neurons start to undergo specification in this region at HH st 16, it is 
possible that Dmrt5 could have a role in midbrain dopaminergic neuron 
development. Furthermore, the temporal anterior to posterior expression pattern of 
Dmrt5 from E9.5 onwards mirrors the way in which dopaminergic neurons are born 
as determined by emergence of TH expression during development [142]. 
The ventricular zone in the midbrain floor plate is the region in which the proliferating 
neural progenitors of dopaminergic neurons are found, and where expression of 
genes involved in specification to dopaminergic fate first occurs [106, 115]. Therefore 
it is possible that expression of Dmrt5 in this region may have a role in maintenance 
of the progenitor pool or specification of these cells to dopaminergic fate. The 
conservation of Dmrt5 expression pattern between mouse and chick, the 
identification of Dmrt5 in the midbrain of Platyfish and Zebrafish, along with the 
strong sequence conservation between vertebrate species provide evidence to 
suggest that the function of this gene could be conserved.  
Outside of the midbrain Dmrt5 expression is detected in the nasal placodes, 
expression of Dmrt4 [196] and Dmrt3 [224] are also found in this region. We 
identified that Dmrt5 is expressed in the dorsal telencephalon of mouse [unpublished 
data, Emily Gale] and chicken, similarly telencaphalic expression of Medaka and 
Xenopus Dmrt4 [225], mouse and chicken Dmrt3 [224] have also been observed. 
While, in the eye, expression of Dmrt2 has been described [217]. Within the lab we 
have used in situ hybridisation and real-time PCR to detect the presence of other 
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Dmrt genes in the midbrain, so far we have not detected any other Dmrt family 
members in the ventral midbrain (Emily Gale). 
In the future it will be interesting to identify if Dmrt5 has a conserved function in these 
different tissues. It has previously been proposed that Dmrt genes act as dimers, 
based on the Dmrt protein structure which contains a C-terminal domain dimerisation 
domain and in vitro studies which show dimerisation between family members [208]. 
As the expression pattern of the Dmrt genes is further investigated it will be 
interesting to see if co-localised genes such as those seen in the nasal placode 
(Dmrt5, 3 and 4) act as dimers [210]. However the focus of this thesis will be to 
investigate the function of Dmrt5 in the ventral midbrain. 
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Chapter 4. Investigating the role of Dmrt5 in midbrain 
development. 
 
4.1 Introduction  
In this chapter I will investigate if Dmrt5 has a role in neurogenesis of the ventral 
midbrain. This hypothesis was driven by evidence that two other DM domain family 
members, Dmrt4 in Xenopus and Mab-3 in C.elegans play a role in neurogenesis, 
via regulation of basic helix-loop-helix (bHLH) proneural genes, neurogenin and Ref-
1 (a Hes homolog), respectively [215, 242]. Ngn2, Hes1 and Hes5 are involved in 
mouse ventral midbrain neurogenesis [114, 117, 243, 244]. Furthermore as 
described in Chapter 3, Dmrt5 expression is temporally and spatially compatible with 
a role in ventral midbrain neurogenesis. 
Neurogenesis within the ventral midbrain occurs from around E10 to E14 in mice, 
with the highest rate at E11.5 [126]. The neurogenic floor plate is characterised by 
proliferative cells within its ventricular zone and expression of proneural genes [114, 
117, 127]. The generation of midbrain dopamine neurons requires the proneural 
gene Ngn2, which is expressed in the ventricular and intermediate zone [114, 117]. 
Mash1, which is also expressed at a lower level in the ventricular zone, is not 
required, but can partially compensate for loss of Ngn2 [117]. Expression of 
proneural genes and proliferation seem to be linked, as loss of Ngn2 prevents cells 
in the ventricular zone from undergoing cell cycle exit [114, 117]. Conditional loss of 
Liver X receptors α and β (Lxr α/β) also reduces ventral midbrain neurogenesis and 
cell cycle exit [245]. Several other genes which affect neurogenesis such as Otx2, 
Wnt2 and Nato3 also affect proliferation, further suggesting there is a link between 
these two processes [130, 139, 244]. 
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Two signalling pathways, key to specification and patterning of the ventral midbrain, 
regulate expression of Ngn2 and cell proliferation, these are the Foxa2-Shh pathway 
and the Wnt1-Lmx1A pathway, these pathways are discussed in chapter 1 and 
illustrated in Figure1.4 [118, 121, 123-125]. 
Along with Shh-FoxA2 and Wnt1-Lmx1A mechanisms that appear to be involved in 
control of neurogenesis, Hes1 also seems to be involved in this process [243, 244]. 
Hes1, a bHLH protein, inhibits expression of proneural genes and is required for 
maintenance of neural progenitors [246-248]. Recently, Nato3 was found to be 
required for cell cycle progression and induction of proneural genes, Ngn2 and 
Mash1, in the ventral midbrain via repression of Hes1 [244]. How these findings 
correlate with previous understanding regarding the role of Otx2, Shh, Wnt, Lmx1A/B 
and Msx1 on neurogenesis is not known. Nato3 appears to be a direct target of 
FoxA2, as two FoxA2 binding sites are found within the promoter of Nato3 which are 
necessary and sufficient for promoter activity [249]. 
Further evidence for the role of Hes1 in the development of the ventral midbrain 
comes from experiments using conditional loss of FGF receptors 1 and 2 (FGFR1/2), 
which demonstrate that FGF signalling is needed for Hes1 expression in the ventral 
midbrain at E10.5 and E11.5. Loss of FGFR1/2 reduces Hes1 expression and results 
in premature neurogenesis and an increase in exit from the cell cycle [243].   
In the following results section in ovo electroporation to exogenously express Dmrt5 
has been employed along with over expression of Dmrt5 during dopaminergic 
neuronal differentiation of Epi Stem cells (EpiSCs) to investigate if Dmrt5 has a role 
in neurogenesis of the ventral midbrain.  
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4.2 Results 
4.2.1 Dmrt5 affects expression of genes involved in neurogenesis 
To explore the role of Dmrt5 in neurogenesis, HH st 10 chicken embryos were 
electroporated with a pCaβ-Dmrt5-IRES-GFP expression construct via in ovo 
electroporation. During in ovo electroporation, DNA is injected into the developing 
anterior neural tube. Electrodes are placed either side of the developing neural tube 
and a current is then passed across the tissue. This current disrupts the cell 
membrane and cells become transiently porous. The negatively charged DNA moves 
towards the positive electrode and is taken up via these pores by cells adjacent to 
the positive electrode. The contralateral side of the embryo serves as an internal 
control for exposure to the electroporation procedure. As a control for exogenous 
expression of DNA, stage matched embryos were electroporated with the same 
concentration of pCaβ-IRES-GFP construct.  
Following in ovo electroporation at HH st 10 embryos were left to develop. No 
change in morphology was observed in embryos 24 hours post electroporation of 
Dmrt5. However, 48 hours after electroporation, the side of the midbrain 
exogenously expressing Dmrt5 was much smaller and thinner than the contralateral 
control side. This effect was not seen when embryos were electroporated with pCaβ-
IRES-GFP. 
To characterise these changes in morphology, midbrains from embryos 
electroporated with pCaβ-Dmrt5-IRES-GFP and pCaβ-IRES-GFP at HH st 10 were 
collected at HH st 26, embedded in OCT and cryostat sectioned at 20µm. Dmrt 
genes have been found to be involved in regulation of neurogenesis in C.elegans, 
Xenopus and Drosophila [225, 242, 250]. To see if Dmrt5 exogenous expression 
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effects neurogenesis, immunofluorescence was performed on midbrain coronal 
sections using an antibody specific for early pan-neuronal marker neuron-specific 
class III β-tubulin (Tuj1). Dmrt5 over expression resulted in a reduction in the number 
cells positive for the neuronal marker Tuj1 relative to the control on the contralateral 
side (Figure4.1A). Over expression of GFP has no effect on the number of Tuj1 
positive cells when compared to its contralateral side (Figure4.1B). 
 
 
 
Figure 4.1. Ventral midbrain coronal sections of HH st 26 embryos electroporated at 
HH st 10 with A. pCaβ-Dmrt5-IRES-GFP B. pCaβ-IRES-GFP, stained with Tuj1 (red), a pan 
neuronal marker, and DAPI (blue).  
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To further characterise the apparent defect in neurogenesis and to confirm this is 
conserved between species, a mouse EpiSC cell line containing a Dmrt5 transgene 
under the control of a doxycycline inducible promoter (this cell line will be described 
as the DA2-5 cell line hereafter), was differentiated towards neuronal fate using the 
monolayer differentiation protocol developed in our laboratory [187] and described in 
Chapters 1 and 2. 
The expression of Dmrt5 during this EpiSC differentiation protocol in the uninduced 
DA2-5 cell line can be seen in Figure 4.2. During dopaminergic differentiation 
exogenous expression of Dmrt5 was induced on day 5 by addition of doxycycline. At 
this time point the cells endogenously express moderate levels of Dmrt5 and 
therefore should contain any co-factors required for the function of this gene.   
 
Figure 4.2. Expression of Dmrt5 during monolayer differentiation of EpiSCs quantified 
by real-time PCR. Bars are the average of 3 biological replicates repeated in triplicate, error 
bars show standard deviation of biological replicates. Expression is normalised to reference 
genes, HMBS, Cyclophilin and beta actin. Data provided by Ines Jaeger. 
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EpiSCs differentiated to dopaminergic fate and induced to exogenously express 
Dmrt5 on day 5 were collected 48 hours later, on day 7 of differentiation. Changes in 
gene expression between uninduced DA2-5 sister culture and induced DA2-5 
samples were analysed by real-time PCR. A fourfold increase in Dmrt5 expression in 
the induced DA2-5 cell line relative to the uninduced DA2-5 cell line resulted in a 
reduction in the expression of proneural markers Ngn2, Mash1, and the Hes1 
repressor, Nato 3. Basic Helix-Loop-Helix (bHLH) transcription factor Hes1, which 
represses expression of proneural genes was up-regulated relative to the uninduced 
control. These findings are consistent with a reduction in neurogenesis [243, 244, 
251]. (Figure 4.3) 
No change in the expression of Ngn2, Mash1, Nato3 or Hes1 were detected upon 
addition of doxycycline to a non-inducible, control (rtTA) cell line  relative to the rtTA 
cell line not exposed to doxycycline (Figure 4.3).  Therefore the changes in gene 
expression observed upon addition of Dmrt5 over expression were not a result of the 
addition of doxycycline. 
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Figure 4.3. Expression of Dmrt5 and neuronal genes in doxycycline induced DA 2-5 
cell line relative to DA 2-5 uninduced (blue).  Non-inducible control rtTA cell line exposed 
to doxycycline relative to rtTA cell line not exposed to doxycycline (red). Expression is 
normalised to reference genes, HMBS, Cyclophilin and beta actin. Data provided by Ines 
Jaeger. 
 
 
The role of Hes1 in inhibition of neurogenesis has been well described. It is known to 
reduce levels of both Ngn2 and Mash1. Therefore the effects of Dmrt5 over 
expression on neurogenesis could be mediated by an up regulation of Hes1. To 
determine if Dmrt5 could be involved in regulation of Hes1 in vivo, the expression 
pattern of both genes was mapped by in situ hybridisation. Dmrt5 and Hes1 are both 
expressed in the ventral midbrain at HH st 16 (equivalent to E9.5 in mouse) (Figure 
4.4A). To investigate if Dmrt5 could up regulate Hes1 in vivo, and to confirm that this 
regulation was conserved in both mouse and chicken, HH st 10 embryos were 
electroporated with pCAβ-Dmrt5-IRES-GFP, incubated for 24 hours, and stained for 
Hes1 by in situ hybridisation. Exogenous expression of Dmrt5, as visualised by 
expression of GFP from the electroporated construct, led to ectopic expression of 
Hes1 (Figure 4.4B). 
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Figure 4.4. Dmrt5 affects expression of Hes1 in vivo. A. In situ hybridisation of Dmrt5 in 
coronal section of ventral midbrain, HH st 16 embryos. B. In situ hybridisation of Hes1 in 
coronal section of ventral midbrain, HH st 16 embryos. C. A whole lateral view of HH st 16 
embryo electroporated with pcaβ-Dmrt5-IRES-GFP. Black line indicates angle of section 
used to obtain E and F D. Whole mount dorsal view of HH st 16 embryonic head 
electroporated with Dmrt5 at HH st 10. E and F. Coronal section of HH st 16 midbrain of 
embryos electroporated with pcaβ-Dmrt5-IRES-GFP and stained for Hes1. Hes1 expression 
is shown in purple, Dmrt5 over expression is shown in green by in situ for GFP 
 
4.2.2 Dmrt5 affects cell proliferation 
Higher levels of Hes1 affect proliferation, maintain cells in a G1 retarded state and 
prevent neurogenesis [246, 251-253]. As Dmrt5 exogenous expression induced 
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ectopic Hes1 expression and caused a reduction in neurogenic gene expression, I 
investigated if Dmrt5 also had an effect on cell cycle. 
HH st 10 embryos were electroporated with pCAβ-Dmrt5-IRES-GFP, pCAβ-Hes1-
IRES-GFP or pCAβ-IRES-GFP constructs, and collected 24 hours later at HH st 16. 
The midbrains of these embryos were then embedded in OCT and sectioned by 
cryostat at 12µm per section. To determine if Dmrt5 exogenous expression alters the 
cell cycle and to confirm the previously published effects of Hes1 over expression on 
cell cycle, immunofluorescence was performed on midbrain coronal sections using 
an antibody specific for Phospho-Histone H3 (Anti-PH3). Phosphorylation of histone 
H3 requires active cdk1 and is an initial event accompanying chromosome 
condensation [254, 255]. As such Anti-PH3 specifically labels chromosomes from 
prophase through anaphase, and therefore it is a marker for entry into mitosis [254].   
The proportion of PH3+ cells in the Dmrt5, Hes1 or GFP electroporated-cell 
population, as marked by GFP expression, were quantified using sectioned 
midbrains of 6 embryos.  As shown in Figure 4.5, both Dmrt5 and Hes1 over 
expression resulted in a decrease of PH3+ cells when compared to embryos 
electroporated with GFP, indicating a reduced number of cells going through mitosis 
under these conditions. 
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Figure 4.5. Effect of Hes1 and Dmrt5 exogenous expression on mitosis. A. Percentage 
of PH3+ electroporated cells, in embryos electroporated with pCaβ-IRES-GFP, pCaβ-Dmrt5-
IRES-GFP or pCaβ-Hes1-IRES-GFP. Counting is based on midbrain sections from 6 
embryos per condition. The average number of GFP expressing cells counted per embryo 
was 312. B. HH st 16 coronal sections of midbrain with PH3 staining in red and exogenous 
expression of the electroporated construct in green. Error bars show standard deviation.  
83 
 
 
To better understand the effect of Dmrt5 on cell cycle regulation, embryos were 
electroporated at HH st 10 with pCaβ-IRES-GFP or pCaβ-Dmrt5-IRES-GFP. At HH 
st 16 embryos were collected and electroporated cells, expressing GFP, were 
isolated and stained for propidium iodide (PI). (Figure 4.6) 
PI is a fluorescent dye that intercalates stochiometrically with RNA and DNA within 
the cells. In the presence of RNAase, the stained cells incorporate an amount of dye 
proportional to their DNA content. The fluorescence is detected and is considered a 
measurement of cellular DNA content. As cells in different stages of the cell cycle 
contain differing amounts of DNA this can be used to identify what stage of the cell 
cycle the cells are in. As G2 and M phase both have identical DNA content these 
cannot be discriminated between based on DNA content. Therefore this analysis can 
only group cells into G1, S or G2-M stages. Cell doublets will report twice as much 
DNA as a single cell. Therefore these and other aggregates need to be removed 
from the analysis. This is done by setting up a series of gates that select only the 
cells which pass certain criteria, such that only the single cells are analysed. 
The selection of single cells is based on several parameters: cell volume as 
measured by forward side scatter and the complexity of the cell (shape of nucleus, 
type of cytoplasmic granules, membrane roughness) by side scatter.  The analysis 
based on side scatter area and forward scatter area allows selection of the cell 
population and removal of debris. Analysis of forward scatter area and width depicts 
doublets and aggregates so that one can select the singlet population. Doublets, 
aggregates and cell debris can also be filtered out of this population by comparing 
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the width and area of the fluorescent signal. Only cells which are selected as singlets 
by all these parameters were used for the analysis.  
The PI staining of GFP positive or Dmrt5 positive single cell populations were 
recorded by flow cytometry. While cells over expressing GFP showed a cell profile 
similar to cells that had not been electroporated, over expression of Dmrt5 caused 
an increase in the number of cells to be held in G1 (Figure 4.6). 
 
 
 
Figure 4.6. Effect of Dmrt5 over expression on cell cycle. A. PI staining profile of ventral 
midbrain cells electroporated with pCaβ-IRES-GFP B. PI staining profile of ventral midbrain 
cells electroporated with pCaβ-Dmrt5-IRES-GFP. 
 
Obtaining large numbers of cells from electroporated embryos for PI analysis is 
difficult. Therefore, the cell cycle profile of EpiSCs differentiated towards neuronal 
fate was measured. As larger numbers of cells can be obtained the defects in cell 
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cycle could be quantitated. Dmrt5 over expression was induced in DA2-5 EpiSCs by 
addition of doxycycline on day 5; cells were then harvested at day 7 and stained for 
PI. The cell cycle profile of the doxycycline induced and uninduced DA2-5 cultures 
were compared using Flow Jo (Figure 4.7A). The difference in cell cycle profiles was 
calculated using the mathematical Dean Jett-fox model (Figure 4.7B). This model fits 
Gaussian curves to the G1 and G2 phases and a polynomial function to the S phase. 
The experiment was conducted using three biological replicates, error bars show 
standard deviation between biological replicates (Figure 4.7C). I found that a 5-fold 
up regulation of Dmrt5 transgene expression caused 10% increase in the proportion 
of cells in G1 (Figure 4.7C, D). This G1 retardation phenotype is also seen when 
Hes1 is over expressed in the mouse E13 telencephalon [251]. 
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Figure 4.7. Effect of Dmrt5 over expression in EpiSCs on cell cycle. A. PI staining of 
uninduced/wild type DA2-5 EpiSCs B. PI staining of DA2-5 induced cell line, over expressing 
Dmrt5 C. Quantification of cell cycle analysis using mathematical model Dean Jett-Fox. Bars 
are the average of three biological replicates, error bars show standard deviation.  D.  Real-
time PCR analysis of genes involved in cell cycle regulation. Expression in Dmrt5 over 
expressing DA2-5 EpiSCs is normalised to the level of these genes in wild type uninduced 
DA2-5 cells. Bar represents average of 3 biological replicates normalised to three control cell 
lines, error bars depict standard deviation. 
 
As the cells appear to be G1 retarded upon Dmrt5 exogenous expression, the 
expression of genes involved in cell cycle regulation were analysed in the induced 
and uninduced DA2-5 cell line by real-time PCR. Induction was carried out on day 5 
and cells were collected day 7. There was little change in S phase marker 
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Proliferating Cell Nuclear Antigen (PCNA) [256], or in G2/M checkpoint genes, Wee1 
[257, 258], Chk1 [259] or Chk2 [260] expression upon Dmrt5 over expression. 
Cyclin D1 is a G1 phase marker, up regulation of this protein has previously been 
described in Hes1 over expressing G1 retarded cells [246, 261]. In line with this 
literature Dmrt5 transgene expression leads to an increase in Cyclin D1. However, 
this gene has also been described to be down regulated upon over expression of 
Hes1 [251]. p21 is a potent cyclin-dependent kinase inhibitor that binds to and 
inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a 
regulator of cell cycle progression at G1. Previously p21 has been reported as up 
regulated in response to Hes1 over expression [261]. However, I did not observe a 
consistent change in p21 expression in response to Dmrt5 over expression. There 
were large error bars for this gene as different samples had different levels of this 
gene but this was not a result of the Dmrt5 over expression. p27 is another cyclin-
dependent kinase inhibitor that can be directly inhibited by Hes1 [262]. While in 
cortical progenitors, expression of p27 has been shown to stabilise expression of  
Ngn2 and promote neurogenesis [263]. I detected a reduction in p27 upon Dmrt5 
over expression. The same effect is observed upon Hes1 over expression [27] 
(Figure 4.5D). These changes in p27 and Cyclin D1 were seen when only 10 % of 
the cells were G1 retarded and with only a 5 fold upregulation of Dmrt5. It would be 
interesting to investigate the change of gene expression occurring in vivo where the 
effect of G1 retardation is far greater. 
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4.2.3 Does Dmrt5 directly control transcription of Hes1? 
In C.elegans, Dmrt5 homolog, Mab-3, binds to the promoter region of Hes homolog, 
Ref-1 [207]. I therefore postulated that Dmrt5 may induce expression of Hes1 via 
binding to Hes1 regulatory elements upstream of its transcriptional start site. To 
investigate this hypothesis, I searched for Dmrt5 consensus sequence binding sites 
in the mouse Hes1 coding sequence and 10kb upstream of this. Two Dmrt5 
consensus binding sequences were found just upstream of the Hes1 promoter 
region, p0 and p2b (Figure 4.8A). ChIP experiments were used to identify if Dmrt5 
could bind to these sequences.  
DA2-5 EpiSCs were differentiated towards neuronal fate. For one experimental 
condition Dmrt5 over expression was induced on day 5, by addition of doxycycline. 
As controls for the addition of doxycycline, the uninduced DA2-5 cultures that 
express endogenous levels of Dmrt5 were used. As a further control, EpiSCs 
homozygous for a predicted Dmrt5 null allele were differentiated using the same 
protocol. 
Cultures from the three cell lines were collected on day 6 and the proteins bound to 
the DNA were cross linked such that these interactions were fixed. The protein-DNA 
complexes were then extracted from the cells and this chromatin was sonicated to 
obtain 200-800 bp DNA-protein fragments. This fragmented chromatin is known as 
the starting material or input. The input is used to calculate how much DNA is initially 
present in each sample and therefore what proportion of the original input is pulled 
down during ChIP. This measurement is called the % input. For the ChIP experiment 
500µl input chromatin was incubated with an antibody specific for Dmrt5. This 
precipitates any DNA to which Dmrt5 protein is cross linked. The protein-DNA cross 
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links are reversed and the DNA fragments are analysed. The amount of DNA 
isolated by this pull down is compared to the starting amount of this DNA in the input. 
To control for non-specific binding, input chromatin from each condition was 
incubated with a non-specific antibody. To control for DNA binding to the beads used 
during the precipitation, for each condition, a sample containing 500µl input 
chromatin but no antibody was also used. To ensure that all samples had been 
treated in a similar fashion during the ChIP experiment, H3 antibody was also 
incubated with input fragmented chromatin from each of the three conditions. As 
similar levels of H3 should be seen in all samples it can be used as a control to 
check that during the ChIP experiment all samples were treated similarly. A similar 
H3 pattern was observed in all 3 conditions (data not shown). 
Real-time PCR using primers designed to locations in the Hes1 promoter and coding 
region were used to detect the amount of DNA that was attached to Dmrt5. The 
regions to which the PCR primers were designed can be seen in Figure 4.8A. These 
are 2 binding sites in the promoter region (p0 and p2b), 1 non-binding site (p-2) and 
a binding site within the coding region (p4) (Figure 4.8A). To calculate if Dmrt5 binds 
to p0 and/or p2b (predicted binding sites) with a higher affinity than at non-binding 
sites, the binding at each site in samples incubated with Dmrt5 antibody was 
compared to the binding obtained for the same condition incubated with non specific 
antibodies to calculate the fold enrichment. As can be seen in figure 4.8B, at non-
binding site p-2 there is a fold enrichment of 1 in all three conditions meaning that 
the non specific antibodies found in the serum and Dmrt5 antibody bind to this region 
with the same affinity. Therefore Dmrt5 does not bind to this region with greater 
specificity than a non specific antibody. Dmrt5 binds to the predicted binding sites p0 
and p2b with a greater affinity than the non specific antibody. At p0 there is 
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enrichment in both Dmrt5 over expression and wild type conditions. It is strange that 
there is a fold enrichment at this site in the Dmrt5 null condition too, as this should 
not contain any Dmrt5 protein and therefore the Dmrt5 null condition should give the 
same levels as the non specific antibody. At the p2b site a more expected profile is 
seen with over expression of Dmrt5 giving highest enrichment, followed by a lower 
level of enrichment in the wild type condition and no enrichment in the Dmrt5 null 
condition. In the p4 site, which is a predicted binding site in an exon of Hes1, only in 
over expressing cells does a specific binding occur. This is less than the enrichment 
seen at the two binding sites within the promoter.  (Figure 4.8B). 
Another way to analyse ChIP data is by comparing the amount of DNA pulled down 
relative to the starting material, the input, defined previously.  This method is 
beneficial as one can see the relative levels of pull down for each condition (Figure 
4.8C). The levels of pull down are much higher in the Dmrt5 over expressing 
condition than in the other conditions, with levels of pull down in the null condition 
very low. The highest % input pull down is seen in p2b site.  
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Figure 4.8. Analysis of Dmrt5 binding to Hes1 promoter. A. Predicted Dmrt5 binding 
sites in Hes1 coding region and upstream of the Hes1 transcriptional start site 
(shown as blue lines). Grey boxes depict sites of PCR primers used. B. Real-time 
PCR of ChIP experiment at these probe sites calculated relative to non specific IgG 
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containing serum control. C. Real-time PCR of ChIP experiment at the described 
probe sites relative to % input.  
4.2.4 Microarray analysis show Dmrt5 has a role in neurogenesis, 
proliferation and differentiation.  
The experiments described in this chapter support the hypothesis that Dmrt5 plays a 
role in neurogenesis of the ventral midbrain. To obtain a more global understanding 
of the function of Dmrt5 during midbrain dopaminergic neuron development, I 
conducted a microarray experiment using HH st 16 ventral lateral midbrain tissues 
from embryos which had been electroporated with pcaβ-IRES-GFP or pCaβ-Dmrt5-
IRES-GFP at HH st 10. The microarray experimental set up and analysis will be the 
topic of the next chapter. However, of relevance to this chapter and in agreement 
with the findings described above, tissue exposed to ectopic Dmrt5 expression 
preferentially affected genes involved in CNS proliferation, CNS differentiation and 
neurogenesis, when compared to embryos exposed to GFP or electric current alone, 
as determined by Ingenuity Pathway Analysis (IPA) (Figure 4.9). The Ingenuity 
Knowledge Base is the largest knowledge base of its kind, with findings curated from 
the full text literature. IPA uses a Fisher's exact test to determine which biological 
functions were significantly enriched within the set of genes showing differential 
expression compared to the entire list of genes represented on the array.  
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Figure 4.9. IPA analysis of microarray data showing that a significant number of genes 
involved in Proliferation of CNS cells, Differentiation of CNS cells and Neurogenesis are 
affected by over expression of Dmrt5 but not GFP.  
 
4.3 Discussion 
In this chapter I provide evidence that Dmrt5 regulates genes which are involved in 
ventral midbrain neurogenesis by altering expression of Tuj1, Mash1, Ngn2, Hes1 
and Nato3 (Figure4.3). Dmrt5 is also involved in cell cycle progression, with over 
expression of Dmrt5 causing G1 retardation of the cells and the change in 
expression of cell cycle genes involved in G1: Cyclin D1 and p27, but no change in 
p21, S phase markers or G2/M checkpoint markers (Figure4.5 and 6). 
Hes1 has only recently been investigated with regard to neurogenesis of the ventral 
midbrain [243, 244]. Here we show Dmrt5 binds to the promoter region of Hes1 and 
can ectopically induce Hes1 expression (Figure 4.7). Furthermore Dmrt5 affects cell 
proliferation and neurogenesis; both of these processes are also affected by Hes1 
[251]. As a result the effects observed upon Dmrt5 over expression may be mediated 
via regulation of Hes1 expression. Over expression of Dmrt5 in cells where Hes1 is 
knocked down could be used to investigate if the neurogenic effect of Dmrt5 over 
expression is exclusively mediated via up regulation of Hes1.  
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Dmrt5 also causes the down regulation of Nato3, a gene known to repress Hes1 
expression and induce neurogenesis. Nato3 is proposed to permanently down 
regulate Hes1 from E10.5 onwards [244]. However this contradicts results reported 
Lahti et al, which shows Hes1 expression is still present at E11.5 [243]. It will be 
interesting to investigate the dynamics of Nato3, Dmrt5 and Hes1 expression during 
neurogenesis (E10.5-14) in more detail and specifically to investigate if they are 
expressed in the same cells. The creation of a good Dmrt5 antibody in 2011 should 
facilitate this process. 
ChIP experiments show specific binding of Dmrt5 to two predicted binding sites in 
the Hes1 promoter. Suggesting that Hes1 is a direct target of Dmrt5, however these 
experiments must be repeated, both with biological replicates and preferably by a 
second method such as Electrophoretic shift mobility assays (EMSA).  
During ventral midbrain development expression of ventral midbrain developmental 
genes, regulation of neurogenesis, cell cycle progression and exit are fundamentally 
linked [114, 117, 119, 244]. Dmrt5 appears to be involved in these processes. Dmrt5 
affects neurogenesis and proliferation of the ventral midbrain, experiments in this 
chapter suggests that this is mediated, at least in part, via regulation of Hes1 
expression. These findings agree with those of Ross et al who previously postulated, 
based on their findings in C.elegans, that regulation of Hes genes by DM domain 
proteins may be a general mechanism [207]. Further experiments are required to 
better understand the way in which Dmrt5 is involved in ventral midbrain 
neurogenesis and regulation of cell cycle. Such experiments should include the 
analysis of mice homo or heterozygous for lack of Dmrt5. 
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Chapter 5. Genome-wide effect of Dmrt5 over 
expression 
 
5.1 Introduction 
In this chapter, I will use a genome-wide approach to investigate the possible 
functions of Dmrt5. It is important to interpret the results obtained from this 
experiment within the biological context of the ventral midbrain ventricular zone, as 
this is where Dmrt5 is expressed during midbrain dopaminergic neuron development. 
Therefore, in the following paragraphs I will summarize the developmental processes 
occurring in this region from the start of Dmrt5 expression at E9.5 (HH st 16).  
When expression of Dmrt5 first occurs, the ventral midbrain is entirely composed of 
a ventricular zone, containing proliferative progenitor cells, this remains the case 
until E10.5 (HH st 22) [107, 264]. From E9.5 (HH st 16) onwards cells start to 
express genes which commit the progenitors to dopaminergic fate such as Lmx1A 
and FoxA2 [115, 123, 124]. These specification factors also prevent expression of 
genes involved in more lateral fates [123] and activate expression of proneural gene 
Ngn2 which is concomitant with cell cycle exit [115]. As this occurs the cells 
transition from the ventricular zone to form a new layer, the intermediate zone, 
containing immature dopamine neurons. These immature neurons activate 
transcription of genes involved in terminal differentiation such as Nurr1 [147, 265, 
266] and Pitx3 [156, 157]. The terminally differentiated cells are located in a third 
layer, the marginal zone, and express TH and other components required for 
dopamine neurotransmission. This process is described in more detail in Chapter 1 
and Figure 1.4. 
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The cells of the ventricular zone give rise to midbrain dopaminergic neurons 
continuously from E10.5 to E14.5 (HH st 22 – HH st 34) as determined by 
expression of TH [103, 106]. During the continuous generation of dopamine neurons, 
cell proliferation only occurs in the ventricular zone, even after the formation of the 
three layers [103, 106]. It has been estimated that the number of cells present in the 
ventral midbrain of a laboratory mouse increases about 10 fold from E10.5 to E12.5 
from 1-2x10e4 to 10-20 x10e4 [264]. As such the ventricular zone provides the 
progenitor population and the proliferative capacity of this region which is crucial to 
the generation of the full complement of dopamine neurons.  
How cells transition from the ventricular zone to the intermediate zone is not well 
understood. It has been shown that cells on the ventricular surface of the ventral 
midbrain as labelled by BrdU progress ventrally from this ventricular zone to the 
marginal zone where they express TH. Electron microscopy showed that the 
immature neurons made close contacts with radial glia cells [267]. This led to the 
perception that the radial glia like cells serve as a scaffold for dopamine neuron 
migration [267, 268] although this has not been experimentally determined.  Further 
studies have shown that cells expressing radial glial markers can undergo 
neurogenesis and give rise to dopaminergic neurons [106]. 
Since each layer of the developing neural tube contains cells in different stages of 
differentiation, progression through the layers may be integrally linked to the 
developmental program of dopaminergic neuron differentiation. However there is 
little research to investigate this. Loss of Ngn2, required for neurogenesis of midbrain 
dopaminergic neurons, causes cells in the ventral midbrain to remain attached to the 
apical surface, with a decrease in number of cells in the marginal zone [114, 117] 
providing evidence that the transition of cells from one layer to the next is linked to 
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the state of the progenitor cell. In support of this, conditional knock out of the 
cadherin-dependent cell adhesion complex, β-catenin [269] which is expressed 
abundantly at the apical side of the ventricular zone, in midbrain dopaminergic 
progenitor cells resulted in severe perturbation in the organization of ventral midbrain 
floor plate and a reduction in cell proliferation and neurogenesis [177].  
In addition to the specific role of the ventricular zone, floor plate cells play an 
important role in guidance of commissural axons by secreting diffusible molecules 
such as netrins [270, 271]. 
To investigate if Dmrt5 is involved in any of these processes which occur in the 
ventral midbrain a microarray experiment was carried out. The aim of the microarray 
experiment was twofold:  
1. To determine if Dmrt5 is involved in patterning of the ventral midbrain, as 
many other transcription factors expressed in ventricular zone promote 
expression of downstream dopaminergic factors and inhibit expression of 
lateral gene fates [119, 123].  
 
2. To identify genes regulated by Dmrt5 to infer other possible functions of this 
gene in the ventral midbrain development.  
To achieve these goals the genome-wide expression profile of Ventral Lateral 
Midbrain (VLM) tissue from HH st 16 (E9.5) chicken embryos exogenously 
expressing Dmrt5 was compared to the expression profiles of stage matched 
controls and to the expression profile of floor plate (FP) tissue, a region in which 
Dmrt5 is normally expressed and which gives rise to dopaminergic neurons. We 
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reasoned that exogenous expression lateral to the normal expression region would 
identify genes that were directly regulated by the transcription factor Dmrt5 and 
pathways downstream of this. Furthermore comparison of the transcriptional profile 
obtained upon Dmrt5 over expression in the VLM to the expression pattern normally 
seen in the FP would provide information regarding the role of Dmrt5 in patterning of 
the ventral midbrain.  
 
5.2 Results 
5.2.1 Experimental strategy 
The experimental design can be seen in Figure 5.1. Pooled samples of VLM tissue 
and a pooled sample of FP tissue were collected. The five samples were: 
Control Condition 
1. Unelectroporated VLM (VLM) 
 
Experimental Conditions  
2. VLM exposed to electric current only (VLMi) 
3. VLM exposed to expression of GFP and electric current (VLMg) 
4. VLM electroporated with Dmrt5 (VLMd) 
5. FP from unelectroporated embryos (FP) 
Each pooled sample contained tissue from 6 stage matched embryos. Exogenous 
expression was achieved by in ovo electroporation of pCAβ-Dmrt5-IRES-GFP or 
pCAβ-IRES-GFP at HH st10. Embryos were collected 24 hours later at HH st16. 
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Following collection of tissue, RNA was extracted, amplified using Ribo-SPIA 
technology which allows linear, isothermal amplification of the mRNA species in a 
total RNA population. Unlike exponential amplification, this linear amplification 
approach is carried out by replication of only the original transcripts not replication of 
copies, resulting in a high-fidelity, robust and sensitive amplification process that 
reflects the original RNA sample. This amplified RNA was then hybridised to 
Affymetrix GeneChip Chicken Genome Microarrays containing probes for 32,773 
transcripts corresponding to over 28,000 genes. For each condition three biological 
replicates were used.  
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Figure 5.1. Experimental strategy A. Dissection of the ventral lateral midbrain (VLM) and 
Floor plate (FP) region. (i) In situ sagital view of a HH st 16 electroporated embryo 
expressing pCAβ-IRES-Dmrt5 construct (dorsal view in the inset). Red lines indicate the 
midbrain region (Mb), which was dissected out.  (ii-iv) Coronal sections of midbrain. White 
lines mark the VLM regions and yellow lines indicate the FP region isolated for microarray 
analysis. The regions isolated for microarray analysis were (ii) control embryos wild type 
VLM (VLM) and wild type floor plate (FP), (iii) VLM exposed to current (VLMi), (iv) VLM 
exposed to current + GFP (VLMg), and VLM exposed to current + Dmrt5 (VLMd; image not 
shown). B.  Tissue processing and microarray analysis. Six VLM tissues were pooled for 
each biological replicate, and three biological replicates were used for each condition. cDNA 
was isolated from these pools and hybridised to the Affymetrix Chicken Genome Array. 
Following Mas5, normalization and filtering, genes whose expression differed significantly 
between the wild type VLM and FP, VLMi, VLMg and VLMd were identified by One-way 
ANOVA, SNK post hoc test and fold change analysis. 
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5.2.2 Data processing - Validation and filtering of microarray data 
 
The hybridisation of labelled samples to the probes on the Affymetrix GeneChip 
Chicken microarrays was calculated from raw data using the Mas5 algorithm 
embedded into the GCOS suite (Version 1.2 Affymetrix). Since many of the genes 
involved in midbrain development are transcription factors, Mas5 was chosen as the 
other commonly used algorithm, RMA, squashes the ends of the data sets so 
information about low expressing genes such as transcription factors would not be 
so easily identifiable [272]. Data were then analysed using the Genespring package 
(version GX11; Aglient technologies).   
 
The suitability of the expression data sets for inclusion in further analysis was 
assessed using three methods. First the 3’/5’ ratio, this measures the efficiency of 
cDNA synthesis reaction. All Affymetrix arrays contain probes for the regions 
corresponding to the 3’, middle and 5’ of housekeeping genes such as GAPDH and 
β-Actin. The ratio of signal intensity of 3’ and 5’ probe sets provides a measure of the 
number of cDNA synthesis reactions that went to completion, good quality RNA 
should result in a ratio of 5’:3’ = 1. A 5’:3’ of greater than 3 indicates that either the 
starting RNA was degraded or there were problems with the cDNA synthesis 
reaction. All 5’:3’ ratios were around 1 and none were 3 or higher. This indicates that 
the RNA was of good quality and the cDNA synthesis reaction occurred correctly.  
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Second the hybridisation controls were analysed. Premixed hybridisation control 
transcripts in known staggered concentrations were added to the hybridisation mix. 
Hybridisation controls are composed of a mixture of biotin labelled cRNA transcripts 
of bioB, C and D and Cre prepared in staggered concentrations. These controls 
enable monitoring of the hybridisation and washing process. The signal intensity 
should increase with concentration. Deviations from the expected intensity profile of 
these controls indicate potential problems with the hybridisation or washing process.  
All samples showed similar and expected profiles of hybridisation.  
 
Lastly the variation in biological replicates was analysed by Principal Components 
Analysis (PCA). PCA is a mathematical procedure that measures the variation in 
expression levels between microarrays. PCA showed all biological replicates cluster 
together, demonstrating that the biological replicate datasets are similar and 
reproducible (Figure 5.2A). 
 
The overall relationship between biological replicates was also assessed using 
quantile plots for each of the 15 microarray data sets. The distribution of gene 
expression across the whole array was monitored before and after normalization by 
quantile groupings and was found to be similar for each set of biological replicates. 
The quantile plots for the normalized values can be seen in Figure 5.2B. 
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Figure 5.2 Validation of microarray data. A. PCA analysis. Each dot represents the 
expression profile from one microarray. Dots are colour coded into biological replicates. All 
biological replicates cluster together, indicating that biological replicates are similar. B. 
Quantile box plot of normalised data for each microarray. The blue box shows the 25th to 75th 
percentile, the band in the middle the 50th percentile of the normalised intensity values from 
each microarray. The end of the whiskers shown in red represents one and a half standard 
deviations from the mean.  
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Having confirmed that all samples passed quality control, probe sets showing 
acceptable values in all 3 biological replicates of any 1 of the 5 conditions were then 
selected. These probe sets were analysed to identify genes significantly differentially 
expressed between the control condition VLM and each experimental conditions. 
This was done using One Way Analysis Of Variance (ANOVA) with unequal 
variance. One-way ANOVA tests allow one to determine if there is a significant effect 
on gene expression behaviour across any of the groups under study relative to the 
control condition. A significant p-value resulting from a one-way ANOVA test would 
indicate that a gene is differentially expressed in at least one of the groups analysed. 
If there are more than two groups being analysed, however, the one-way ANOVA 
does not specifically indicate which pair of groups exhibits statistical differences. 
Post Hoc tests can be applied in this situation to determine which specific pair or 
pairs show significant differential expression. 
 
The Post Hoc test chosen was Student-Newman-Keuls (SNK) test. In this test all 
means for each condition are ranked in order of magnitude, with the group with 
lowest mean gets a ranking of 1. The pairwise differences between means, starting 
with the largest mean compared to the smallest mean, are tabulated between each 
group pair and divided by the standard error. This value, q, is compared to a critical 
value. If q is larger than the critical value, then the expression between that group 
pair is considered to be statistically different. The SNK test is slightly less 
conservative than the Turkey test, the other common Post Hoc test, and this is why it 
was chosen. Multiple testing correction is a way to remove false positives from the 
list of differentially expressed genes, however it is often too stringent for biological 
tests therefore it was not used. 
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Of these genes showing a significant differential expression (p <0.05) those with a 
≥1.5 fold change from the level in the control condition relative to an experimental 
control were selected. The number of probe sets differentially expressed between 
each experimental condition and the control condition can be seen in Table 5.1.  
 
 
 
 
Experimental condition  Number of probe sets showing a 
significant differential expression 
relative to the control condition 
(VLM) (p <0.05, fold change ≥1.5) 
VLMd 1783 
VLMg 555 
VLMi 450 
FP 1381 
 
Table 5.1. Number of probe sets showing significant differential expression (p <0.05) 
and ≥ 1.5 fold change between experimental condition and control condition VLM.  
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Any probe sets showing a change in expression upon exposure to current (VLMi) or 
GFP (VLMg) were removed from further analysis (Figure 5.3), as these changes 
could be an artefact of the electroporation technique. Following removal of these 
probe sets 1545 probe sets were differentially expressed between VLMd and control 
VLM. This included 296 down regulated and 1229 up regulated probe sets. 
 
 
 
 
 
 
 
Figure 5.3. Identification of probe sets significantly differentially expressed (p <0.05) 
and showing a ≥1.5 fold change in VLMd relative to VLM but not affected in VLMg or 
VLMi relative to VLM. 
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5.2.3 Dmrt5 role in floor plate transcription 
 
In Figure 5.4 the normalized intensity value for each probe set significantly 
differentially expressed (p <0.05, fold change ≥1.5) between the VLMd and VLM is 
represented as a line. The lines are colour coded based on fold change from VLMd 
to VLM with red indicating up regulation and blue down regulation. Exogenous 
expression of Dmrt5 causes a large number of genes to display an expression profile 
similar to that in the FP. This led to the hypothesis that Dmrt5 may induce a 
transcriptional profile similar to that of the floor plate, the region from which 
dopaminergic neurons arise and the region where Dmrt5 is endogenously expressed 
(Figure 5.4). 
 
 
 
Figure 5.4. Profile plots.  A. Profile plot of probe sets differentially expressed between the 
VLMd and VLM. B. Profile plot of probe sets differentially expressed between the VLMd and 
VLM which show a similar expression profile to the FP. 
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To investigate this hypothesis further we identified probe sets which were up 
regulated in both the VLMd and FP conditions, and genes down regulated in both 
VLMd and FP conditions relative to the VLM. As the null hypothesis I carried out the 
opposite comparison of genes which were up regulated in the VLM and VLMd 
conditions, and genes down regulated in VLMd and VLM conditions. These findings 
are summarised in Table 5.2.  
 
 
 
 
 
 
 
 
 
Table5. 2. Probe sets differentially expressed in VLMd relative to VLM, divided into up 
and down regulated FP genes. 
 
Hypergeometric testing was carried out to see if the trend observed in the expression 
profile plots was statistically significant. This was calculated using the phyper 
function in R. The trend that Dmrt5 exogenous expression in the VLM induces a FP 
like character is significant (p=5e-116) whilst the opposite hypothesis has a p=0.27 
and therefore is not statistically significant (Figure 5.5). 
 Up in FP  Down in FP 
Up in Dmrt5 266 31 
Down in Dmrt5 55 61 
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Figure 5.5. Hypergeometric testing of the hypothesis that Dmrt5 induces a FP like 
transcriptional profile. A. Evidence in support of this hypothesis B. Evidence in support of 
the opposite hypothesis that Dmrt5 induces a transcriptional profile similar to that of the 
VLM.  
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5.2.4 Analysis of genes differentially expressed in VLMd and FP relative 
to VLM  
To determine the function of genes regulated by Dmrt5 and normally found in the FP, 
this probe set list was analysed using Ingenuity Pathway Analysis (IPA) v8.0-2602. 
The Ingenuity Knowledge Base is the largest knowledge base of its kind, with 
findings curated from the full text literature. For analysis, the Affymetrix Chicken 
Genome Array gene list was used as a reference set. All data sources, all species, 
and all nervous system tissues and cells were used for the analysis. IPA uses a 
Fisher's exact test to determine which biological functions were significantly enriched 
within the set of genes showing differential expression compared to the entire list of 
genes represented on the array. One reason for choosing IPA was that this analysis 
allows selection of the Chicken genome as a reference set from which to identify 
significantly enriched categories. 
The biological categories of the genes differentially expressed in the VLMd and FP 
relative to the VLM can be seen in Figure 5.6A.The most significantly affected 
molecular and cellular function is “Cellular growth and proliferation”. The second 
most common function is “Cellular movement” within this category the genes listed 
are involved in migration of eukaryotic cells, migration of brain cells and guidance of 
axons. Within “Cellular assembly and organization”, growth of neurites is the most 
affected function. Within the category “Cell-cell signalling and interaction” the 
majority of genes have a role in adhesion of cells. Whilst within the category “Cellular 
development” most genes are involved in differentiation of neurons. In accordance 
with the findings that Dmrt5 up regulates Hes1 identified in Chapter 4; Hes1 is found 
by this analysis as normally present in the FP and ectopically induced in the VLMd 
relative to VLM.  In agreement with the findings that genes involved in cellular 
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movement, cell adhesion and neurite growth are affected in the VLMd and FP 
changed gene list, “Axonal guidance” and “Actin cytoskeleton” canonical pathways 
are significantly enriched (Figure 5.6B). 
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Figure 5.6.  Analysis of the list of genes with the same fold change trends in VLMd 
and FP relative to VLM A. Molecular and cellular functions associated with this gene list 
using IPA. B. Canonical pathways associated with this list of genes using IPA. The 
significance of the association between the data set and functions or canonical pathway was 
measured by a Fischer’s exact test. This calculates a p-value determining the probability that 
the association between the genes in the data set and the function or pathway is explained 
by chance alone, a p value of < 0.05 is considered significant and is marked by the threshold 
line. For canonical pathway analysis a second method to determine significance is also 
carried out this is the ratio of the number of differentially expressed transcripts from the data 
set that map to the pathway divided by the total number of molecules that exist in the 
canonical pathway (right y axis). 
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Gene  Fold change Gene  Fold change 
UNC13C -4.60 DLK1 -1.81 
ALDH1A3 -3.92 ADAMTS6 -1.80 
C13orf15 -2.99 CABLES1 -1.78 
PCNX -2.95 MTHFD1 -1.75 
IL17RD -2.71 PTPRZ1 -1.74 
SPRY2 -2.68 RAD54L -1.73 
LOC421644 -2.59 CPSF2 -1.71 
RASL11B -2.50 ZFP106 -1.69 
FGF18 -2.41 GTPBP5 -1.69 
DIO3 -2.39 LIPA -1.68 
PITPNC1 -2.37 FGF13 -1.68 
FGF3 -2.34 METT5D1 -1.65 
PLCH1 -2.15 EPHB6 -1.59 
MEIS2 -2.15 ARRDC4 -1.59 
VIP -2.10 LOC423506 -1.58 
ELMOD1 -2.01 GLI3 -1.58 
C6orf163 -1.95 SIPA1L1 -1.58 
USP44 -1.94 SSB -1.56 
ST3GAL5 -1.93 ZNF516 -1.56 
CEP152 -1.91 WNT7A -1.56 
RAB3IP -1.88 TYW3 -1.54 
MAPKAP1 -1.87 SLC24A5 -1.51 
TPH2 -1.83 SOAT1 -1.50 
 
Table 5.3.Genes showing down regulation (≥ 1.5 fold change, p <0.05) upon 
exogenous expression of Dmrt5 in the VLM and which are down regulated (≥ 1.5 fold 
change, p <0.05) in the FP relative to VLM. 
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Gene  
Fold 
Change Gene  
Fold 
Change Gene  
Fold 
Change Gene  
Fold 
Change 
S100A6 216.22 
AKAP
14 8.07 
ITGB5 
3.51 FSTL4 2.12 
LOC3951
92 203.34 
COL6
A1 7.96 
LOC768
772 3.51 
SEMA
3F 2.09 
LOC4278
38 137.35 
IGSF1
1 6.63 ST14 3.51 
SNTB
1 2.04 
WFDC2 67.73 
CITED
4 6.45 SDK2 3.48 
PACS
2 2.04 
FABP3 64.70 
LINGO
3 6.42 
LOC425
593 3.44 
BTBD
11 2.03 
LCAT 56.24 GLUL 6.23 KIF9 3.33 
CCDC
91 2.01 
ATP2A3 55.31 
RAB8
B 6.16 PTGDS 3.28 
RCJM
B04_9
b22 2.01 
CFI 42.45 
CXorf3
6 5.99 KRT19 3.27 
IGFBP
7 2.01 
CRYBA2 40.92 
GPSM
1 5.87 NHSL2 3.25 
C10orf
63 1.98 
THPO 26.28 
RSPH
1 5.62 
PCMTD
1 3.22 
C9orf7
5 1.97 
RPRML 24.46 TNS1 5.44 NME1 3.18 
DUSP
14 1.97 
CALB2 22.75 
KIAA1
529 5.32 EDG4 3.12 OTOR 1.94 
LOC4308
80 18.04 
LOC41
6899 5.26 IGFBP2 3.09 
CLDN
11 1.93 
ACE 17.34 
SARD
H 5.16 NFRKB 3.07 
NPDC
1 1.91 
CNRIP1 16.23 YPEL2 5.12 DCN 3.05 
FOXA
2 1.87 
PPL 15.88 
RCJM
B04_3
a16 4.95 
LOC417
151 3.01 
RNF12
8 1.85 
RASD1 14.61 
VDAC
1 4.87 WDR52 2.96 
COL5
A1 1.85 
PNAT10 14.39 
CALD
1 4.82 
FRMD4
B 2.93 
BCAR
1 1.84 
RTN4R 13.59 
ITGB1
BP2 4.65 FGF12 2.85 
CLCN
7 1.83 
PDGFB 13.58 KDR 4.62 
SLC9A3
R1 2.85 PELI2 1.82 
115 
 
TMEM51 13.57 RAB26 4.61 NMI 2.81 PGM3 1.81 
TUBA4A 13.55 
CXCL
12 4.58 JDP2 2.81 
TXND
C16 1.80 
SCG2 13.25 HES1 4.54 PCDP1 2.72 FN1 1.80 
CHRD 12.99 
S100A
11 4.43 CDKL2 2.68 VTN 1.79 
LOC7723
56 12.79 
TMEM
63C 4.31 CREG1 2.60 PSAP 1.78 
PLP1 11.06 
FAM2
0A 4.29 DNAI2 2.57 DAP 1.78 
LOC4254
03 11.02 
UNC5
B 4.24 
LOC424
678 2.56 
CTHR
C1 1.76 
FAM101B 10.71 
RCJM
B04_1
d13 4.17 
LOC424
161 2.54 
NCAM
1 1.73 
MMP28 10.70 
EPB41
L3 4.12 FZD4 2.47 
IFNAR
2 1.72 
STK10 10.52 
IGFBP
5 4.08 OLFM1 2.44 
PEX11
G 1.69 
RAPGEF3 10.27 
CADM
1 3.98 
RCJMB
04_6f1 2.43 
ZDHH
C23 1.68 
GDPD5 10.09 
CREB
3L2 3.93 DNAI1 2.42 
SLC16
A2 1.63 
PLXNA2 9.99 
ARHG
EF9 3.93 
SLC16A
6 2.40 
LRRC
48 1.62 
LTF 9.86 
EFEM
P1 3.88 MYL9 2.33 CPE 1.58 
DYDC1 8.96 
LOC39
5611 3.82 ANXA2 2.32 
SLC17
A5 1.57 
COL9A1 8.68 
ANXA
6 3.63 
LOC420
008 2.26 
GGTL
3 1.56 
OLFML3 8.56 RHOJ 3.59 STYK1 2.26 JAZF1 1.55 
DLC1 8.19 
ARRD
C1 3.57 
LOC422
229 2.21 
ENTP
D2 1.53 
 
 
 
Table 5.4.Genes showing up regulation (≥ 1.5 fold change, p <0.05) upon exogenous 
expression of Dmrt5 in the VLM and which are up regulated (≥ 1.5 fold change, p 
<0.05) in the FP relative to VLM. Hes1 is shown in Bold. 
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5.2.5 Genes differentially expressed upon exogenous expression of 
Dmrt5.  
At the time of tissue collection for the microarray, expression of Dmrt5 is only just 
initiated in the most anterior region of the ventral midbrain. Therefore the 
endogenous functions of Dmrt5 in the floor plate (FP) may be missed by analysis of 
genes that are differentially expressed both upon exogenous Dmrt5 expression in 
the VLM and in the FP relative to the VLM at HH st16. To identify other genes 
regulated by Dmrt5 which may be involved in later midbrain dopaminergic neuron 
development, all genes significantly differentially expressed (p <0.05, fold change ≥ 
1.5) in the VLMd condition relative to VLM were analysed by IPA.  
As was the case in the genes set showing a fold change in both the FP and VLMd 
relative to VLM in the previous section, and in accord with the findings described in 
Chapter 4, “Cell growth and proliferation” was the most significantly enriched 
biological category with 32 molecules. The category “Cell movement” contains 38 
molecules; within this category most of the genes are involved in migration of cells 
and guidance of axons. Within the 3rd most significantly enriched function, “Cell-cell 
signalling and interaction”, 18 molecules involved in attachment and adhesion were 
affected. The category “Cellular development” contains 40 molecules most of which 
have been cited to effect differentiation of neuronal cell lines or in vivo are involved in 
differentiation of central nervous system tissue. “Gene expression” and “Lipid 
metabolism” were also significantly affected, as was “Cell death”. Figure 5.7A. 
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Figure 5.7. Analysis of the list of genes with fold change in VLMd relative to VLM.   
A. Molecular and cellular functions enriched for in the list of genes significantly differentially 
expressed in the VLMd relative to VLM.B. Canonical Pathways significantly enriched for in 
the genes showing significant differential expression in the VLMd relative to VLM condition. 
The threshold shows p= 0.05, therefore any bars above this line are categories which are 
significantly enriched. The ratio (B) (right y-axis) is the number of differentially expressed 
probe sets from the data set that map to the pathway divided by the total number of 
molecules that exist in that pathway. 
 
Analysis of the canonical pathways significantly enriched in the Dmrt5 gene set 
revealed that genes regulated by Dmrt5 which can be directly linked to a function 
during midbrain dopaminergic development are “Axonal Guidance signalling” (the 4th 
most significant pathway) and “Reelin signalling in neurons” (the 5th most significant 
pathway). The most enriched pathway was “Virus entry via endocytic pathway”, 
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“Leukocyte extravasion signalling” and “Clatherin-mediated endocytosis signalling”. 
“FGF signalling” and “Wnt/beta catenin signalling” were also slightly but significantly 
enriched.  
5.2.6 Validation of the microarray by real-time PCR of a selection of candidate 
genes. 
Microarray analysis and subsequent IPA analysis of the data sets identified that the 
genes affected by exogenous expression of Dmrt5 in the VLM are involved in the 
functional categories “Cell growth and proliferation”, “Cellular movement”, which 
largely consists of genes involved in cell migration and axon guidance. “Cell-cell 
signalling and interaction” is also significantly enriched, with most of the genes 
involved in this function cited as involved in attachment and adhesion. “Cellular 
development” was also a significantly enriched category within which genes involved 
in differentiation of neurons are the most common. Furthermore, comparison of 
genes differentially expressed between VLMd and VLM and FP and VLM 
respectively showed that Dmrt5 exogenous expression in the VLM promotes a 
transcriptional profile that is statistically significantly similar to that of the FP.  
To validate these findings, the expression of genes involved in these categories were 
analysed in VLM, FP, VLMd and VLMg samples by real-time PCR. All candidate 
genes selected were chosen from the genes significantly differentially affected in the 
same way in both VLMd and FP relative to VLM. By selecting this set of genes the 
finding that Dmrt5 exogenous expression in the VLM induces a transcriptional profile 
similar to the FP could also be validated by real-time PCR. These can be seen in 
Figure 5.8.  
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Figure 5.8. Validation of microarray and IPA analysis. Real-time PCR of genes involved 
in each of the major categories significantly affected by exogenous expression of Dmrt5 in 
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the VLM. Expression is relative to expression in the VLM, each bar graph is an average of 
three biological replicates, and each biological replicate contained tissue from 6 stage 
matched embryos. Error bars show standard deviation.  
 
No previous publications have described the role of Dmrt5 or members of this gene 
family in cell adhesion and cell migration. However, in agreement with these findings 
from the microarray, in ovo electroporation of Dmrt5 into the midbrain does disturb 
the cellular morphology (Figure 5.9). As can be seen in Figure 5.9 midbrain 
neuroepithelial cells overexpressing GFP at HH st 16 attach to the apical and basal 
laminar creating long cells spanning the width of the epithelium. However upon 
overexpression of Dmrt5 cells no longer have this linear morphology and are round 
with some cells having no attachment to either the apical or basal laminar. 
 
Figure 5.9. Coronal Sections of HH st16 midbrains electroporated at HH st10 with (A) 
pCAβ-IRES-GFP or (B) pCAβ-Dmrt5-IRES-GFP. Sections are stained with DAPI to show 
nuclei (blue); green is expression of GFP from electroporated construct. Cells over 
expressing Dmrt5 (B) display an unusual morphology.   
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5.2.7 Identification of novel genes expressed in the floor plate 
 
Comparison of the transcriptional profile of the VLM and FP at HH 16 provides a 
snap shot of the gene expression present in the ventral midbrain just after the 
midbrain region has been defined as and such provides information about the gene 
expression profile of the ventral midbrain as specification of midbrain dopaminergic 
neurons is initiated. Therefore the genes up regulated in the FP relative to the VLM 
may lead to a better understanding of the developmental program involved in 
formation of midbrain dopaminergic neurons. To look at the functions in which these 
genes are involved, the genes differentially expressed in the floor plate and VLM 
were analysed by IPA. 
The top cellular and molecular functions significantly enriched for in this data set are 
“Cellular movement”, “Cell growth and proliferation”, “Cellular assembly and 
organisation” and “Cell development”. Interestingly “Cell death” is the 5th most 
significant cellular and molecular function in normal floor plate cells. The canonical 
pathways affected are shown in figure 5.10. “Axonal guidance” is the most affected 
category, followed by several which have no function in development of the midbrain 
such as “Hepatic fibrosis”, “Basal cell carcinoma signalling” and “Atherosclerosis”. 
“Human embryonic stem cell pluripotency” is the 8th most significant category. 
“Wnt/beta catenin signalling” is also significantly enriched. 
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Figure 5.10. IPA analysis of genes differentially expressed between the FP and VLM. 
A. Molecular and cellular functions significantly enriched in the genes differentially 
expressed in this data set. B. Canonical functions significantly enriched by this gene list. The 
significance of the association between the data set and functions or canonical pathway was 
measured by a Fischer’s exact test. This calculates a p-value determining the probability that 
the association between the genes in the data set and the function or pathway is explained 
by chance alone, a p value of <0.05 is considered significant and is marked by the threshold 
line. For canonical pathway analysis a second method to determine significance is also 
carried out this is the ratio of the number of differentially expressed transcripts from the data 
set that map to the pathway divided by the total number of molecules that exist in the 
canonical pathway (right y axis). 
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Looking at the list of genes found to be up regulated in the FP relative to the VLM 
(Table 5.5), Shh is the 20th highest up regulated gene with at 18 fold change 
between the FP and VLM. Nato3 is the 5th highest. Both of these genes are known to 
be expressed in the FP, adding confidence to the results of the microarray.  The top 
60 most up regulated genes are shown in Table 5.5. These provide possible 
candidate genes for understanding the mechanism involved in midbrain 
dopaminergic development.  
Many of the genes in this table have previously been detected as expressed in the 
ventral midbrain by in situ between E10.5 – E18.5, these are marked with an *. In 
bold are genes which have been shown to be involved in ventral midbrain 
development.  
 
Fold Change Gene Fold Change Gene 
187.12 
ADRA1B* 
[273] 13.35 LMO7*[274] 
83.21 PDLIM3*[275] 12.84 CHRD 
77.39 ECM2*[276] 12.18 EFEMP1 
67.35 ATP2A3 11.85 VSNL1* [273] 
49.70 
FERD3L[244, 
249] 11.73 MAOA [277] 
38.74 NXPH1* [276] 11.70 LCAT 
31.67 VAV3* [276] 11.38 HES1[243, 244] 
28.73 PPFIBP2 11.24 FABP3 
26.04 MLC1* [276] 10.60 PAP2D 
25.71 
CRYBA2* 
[276] 10.39 LOC772356 
23.91 FAS 10.38 FOXD3* [278] 
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21.76 GAL* [273] 10.26 
ADCYAP1R1*[27
9] 
21.71 CD247 * [273] 10.18 GDPD5*[276] 
21.47 MAP7 9.98 PNAT10 
20.89 CAPN8 9.84 CAPN2 
20.62 
CALB2[273, 
280] 9.77 AKAP14 
20.47 THPO 9.41 LOC415713 
19.53 EPB41L3*[273] 9.39 MEOX2 
18.27 
SHH[69, 99, 
110] 9.26 LOC768920 
18.07 OTOR 8.98 GRIA2*[276] 
17.96 ALC 8.70 DLC1 
17.15 CKMT2 8.50 SCG2*[277] 
17.14 GABBR2[281] 8.50 LOC423138 
16.85 FAM38B 8.14 DYDC1 
16.44 CELSR1 8.10 RELN[282, 283] 
16.17 WDR65 8.00 CXorf36 
15.44 COL9A1 7.90 DISP1*[104] 
14.90 
WIF1*[277, 
284] 7.79 LMX1B[131] 
14.30 STK10*[276] 7.78 IGSF11 
14.05 TEKT5 7.45 ARHGAP24 
13.71 SLIT2 [285]   
 
Table 5.5. Top 60 genes up regulated in the FP relative to the VLM and their fold 
change. Genes in bold have been described to have a role in midbrain dopaminergic neuron 
development.  * marks genes which have been shown to be expressed in the ventral 
midbrain. 
 
125 
 
5.3 Discussion 
 
In this Chapter I aimed to determine if Dmrt5 was involved in patterning of the ventral 
midbrain and infer other possible functions of the Dmrt5 gene during midbrain 
dopaminergic neuron development.  
Comparison of FP, VLM and VLMd transcriptional profiles found that Dmrt5 
exogenous expression in the VLM significantly induced a floor plate like 
transcriptional profile. The precise mechanism by which Dmrt5 induces this profile 
remains to be elucidated. As endogenous Dmrt5 expression in the FP starts at the 
time of the microarray analysis, and since this gene is thought to act as a repressor 
(Xinsheng Nan, unpublished data) Dmrt5 may act to promote a FP like 
transcriptional profile via repressing more lateral fates. This concurs with findings 
from investigations using neuronal differentiation of embryonic stems to 
dopaminergic fate to study  the function of Dmrt5 [286]. To further investigate the 
role of Dmrt5 in the regulation of floor plate transcription, analysis of embryos lacking 
Dmrt5 as well as microarray analysis of embryos over expressing and null for Dmrt5 
at later stages of development would help refine our understanding. 
By comparing the analysis of the list of genes showing similar transcriptional profiles 
in the FP and VLMd, and analysis of all genes significantly differentially expressed in 
the VLMd, I hoped to identify functions of Dmrt5 which may be important at later 
stages in development. However the molecular and cellular functions and canonical 
pathways significantly enriched for in these two data sets are very similar, with the 
exception of the canonical pathway “Reelin signalling pathway” which is enriched for 
in the VLMd condition. 
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Reelin signalling is important for proper migration and positioning of neurons during 
brain development. Within dopaminergic neuron development, lack of Reelin causes 
incorrect positioning of the neurons [282, 283]. However, exactly how positioning is 
affected is not clear and there is contradictory evidence suggesting this pathway may 
have a role in both radial migration, thought to be involved in the migration of cells 
from the ventricular zone to the marginal zone [267, 268], and tangential migration 
which is seen during migration of the developed neurons to target structures [287]. 
As well as obtaining information on the genes affected by exogenous Dmrt5 
expression, this microarray provides data regarding the transcriptional profile of the 
floor plate of the developing chick midbrain at HH st 16 (E9.5), the onset of 
specification . This data set provides a useful source of candidate genes which may 
be involved the developmental processes occurring in this region at this time. 
Analysis of this data set identified genes involved in “Cell growth and proliferation” 
are enriched in this region, as this is a highly proliferative region this is an expected 
finding. Unexpectedly the FP appears to be enriched for genes involved in “Cell 
movement”, “Cell adhesion” and “Cell morphology”. In accordance with these 
biological functions, canonical pathway analysis shows “Axonal guidance” as the 
most enriched category. These categories were also enriched for in the list of genes 
differentially expressed upon Dmrt5 exogenous expression in the VLM.  
At the time the tissue was collected for microarray analysis, the FP consists of a 
pseudo stratified layer of cells which have both apical and basal connections, the 
nuclei migrate between these two locations, with cell division occurring at the apical 
side [106, 177]. The first dopaminergic neurons begin to reach the marginal zone at 
around E10.5 and begin to extend neurites at E11.5 [288]. Therefore the reason so 
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many genes involved in cell movement, cell adhesion, and axonal guidance are 
enriched in this region from HH st 16 (E9.5) is not clear. 
There is little experimental evidence regarding the process by which the cells transit 
from the ventricular to intermediate and then marginal zone. It is thought that it 
occurs via migration of dopamine progenitors along radial glia cells [267, 268]. 
However this is based on observation of radial glia markers and BrdU labelled TH 
expressing cells being in close proximity to each other [267], rather than perturbation 
experiments.  The finding that these radial glia cells appear to give rise to dopamine 
neurons themselves further complicates the situation [106]. Beyond this, there is 
some evidence that disruption of the attachment of cells to the ventricular zone 
prevents correct organization of the three layers of the ventral midbrain and affects 
the proliferation and neurogenesis of midbrain dopaminergic progenitors [177]. 
Indeed as each layer contains cells in a different stage of development it has long 
been thought that transition may be linked to developmental stage. In further support 
of this hypothesis loss of Ngn2 causes cells of the ventral midbrain to remain 
attached to the apical surface in an undifferentiated state [114, 117].  
The gene lists obtained for the FP and VLMd are enriched for genes involved in cell 
movement, cell adhesion and axon guidance. As such these lists could provide a 
starting point to better understand how cell transition from one layer to the next. In 
support of the microarray findings the change in cell morphology seen upon over 
expression of Dmrt5 does suggest Dmrt5 has some role in cellular adhesion and 
movement. Furthermore it would be interesting to try and integrate the findings from 
Chapter 4 regarding the role of Dmrt5 in neurogenesis and cell proliferation with the 
transition of cells from the ventricular zone to the marginal zone.  
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In conclusion the data obtained in this chapter provides a rich source of information 
on which to base further experiments regarding the role of Dmrt5 in cellular 
proliferation and differentiation, as well its role in cell movement, adhesion and 
axonal guidance. The findings of the microarray also provide a description of the 
genes expressed in the FP at the onset of specification and as such provide a list of 
candidates which may be important during this process. Furthermore this candidate 
list of FP genes will allow investigation into the role of cell movement, adhesion and 
axonal guidance molecules in the FP at this time point.  
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Chapter 6. Discussion 
 
This thesis set out to investigate the hypothesis that Dmrt5 is involved in midbrain 
dopaminergic neuron development. This theory was based on 3 pieces of 
information. 
1. Identification of Dmrt5 from a microarray screen, which compared the 
expression of the ventral midbrain to more lateral region, at E12.5. 
2. The localisation of Dmrt5 to the region from which dopaminergic neurons 
arise by in situ hybridisation. 
3. The role of other Dmrt proteins in development. 
This hypothesis was addressed in Chapters 3-5. 
In Chapter 3, I characterised the spatial and temporal expression pattern of Dmrt5 in 
the chicken embryo during the development of midbrain dopaminergic neurons. I 
found that Dmrt5 is expressed within the ventricular zone from HH st16 or E9.5 up 
until at least HH st34 (~E14.0). The ventricular zone in the midbrain floor plate is the 
region where proliferating neural progenitors of dopaminergic neurons are found and 
where expression of genes involved in specification to dopaminergic fate first occurs 
[106, 115]. Based on this information, regarding the expression of Dmrt5, I further 
refined the hypothesis to investigate whether Dmrt5 is involved in maintaining the 
progenitor population, neurogenesis or specification of these cells to dopaminergic 
fate. 
In Chapter 4, I used an inducible Dmrt5 epistem cell line to over express Dmrt5 
during differentiation of these cells to dopaminergic fate. For in vivo studies I used in 
ovo electroporation to exogenously express Dmrt5. These studies identified that 
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exogenous Dmrt5 leads to a decrease in the number of neurons, as detected by 
antibody staining for Tuj1, a decrease in the expression of proneural gene, Ngn2 as 
detected by real-time PCR, and a decrease in cell proliferation with cells being held 
in a G1 retarded stage.  The up regulation of Hes1 in the mouse telencephalon also 
results in these effects [251]. Furthermore, Hes1 was found to be up regulated by 
Dmrt5 in vitro in epistem cell-derived neural progenitors and is ectopically expressed 
in vivo upon exogenous expression of Dmrt5. Conversely, the Hes1 repressor Nato3 
was down regulated in mouse epistem cell model upon over expression of Dmrt5. 
Previous literature has described a direct regulation of Hes1 homolog, Ref-1, by 
Dmrt homolog Mab-3 in C.elegans [242]. Moreover, expression of Drosophila Dmrt 
homolog, dsx, in C.elegans had the same effect, suggesting that this direct 
regulation was conserved [192]. To investigate if mouse Dmrt5 directly regulates 
mouse Hes1, I searched for Dmrt5 consensus binding sites in the region upstream of 
Hes1 transcriptional start site. Dmrt5 binding sites were found and initial ChIP 
experiments suggest Dmrt5 binds to these sites with greater affinity than non-specific 
antibodies. These experiments indicate that Dmrt5 can regulate Hes1 directly. This 
work was described in Chapter 4. 
In Chapter 5 I studied the genome-wide effect of over expressing Dmrt5 ectopically 
in the ventral lateral midbrain of HH st 10 chicks for 24 hours. As Dmrt5 is expressed 
in the ventricular zone and is involved in neurogenesis and regulation of the cell 
cycle I wanted to investigate if it was involved in patterning of the ventral midbrain. 
As described in the introduction, several other genes that regulate expression of 
Ngn2, a key mediator in midbrain dopaminergic neurogenesis, are also involved in 
repressing lateral fates of the Red Nucleus (RN) and Ocular Motor (OCM) neurons 
and promoting the ventral midbrain fate, which is permissive to dopaminergic neuron 
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development. Examples of this include Lmx1A [103], FoxA2 in combination with 
Lmx1A [118, 123, 124] and Otx2 [122, 139]. 
By comparing the transcriptional profile of the floor plate (FP) and that of VLM 
ectopically expressing Dmrt5, I found that Dmrt5 ectopic expression did induce a 
profile similar to the floor plate. Therefore, Dmrt5 is involved in patterning of the 
ventral midbrain. Furthermore, IPA analysis revealed that FP-enriched and Dmrt5 
induced genes are involved in cell growth and proliferation, cell movement, cellular 
attachment and adhesion were affected in both conditions. In accordance with these 
findings, ectopic expression of Dmrt5 in the ventral midbrain cells resulted in an 
unusual morphology where cells were not attached to the basal or apical layers. 
In summary, Dmrt5 regulates expression of Hes1 and neurogenesis, affects cell 
proliferation, cell movement, adhesion and migration. These findings strongly 
implicate a role for Dmrt5 in development. Further research, including loss of 
function studies, will now be able to build on from this work to determine the precise 
role of Dmrt5 in these processes.  
In the following sections I will discuss aspects of the thesis in more detail and 
discuss the findings in the context of the current literature.  
 
6.1 The role of Hes1 in midbrain dopaminergic development 
Hes1, a basic Helix-Loop-Helix (bHLH) gene, inhibits expression of proneural genes, 
is required for maintenance of neural progenitors and regulates the timing of their 
differentiation into neurons [246-248]. Thus in the nervous system, Hes genes are 
critical for generating the correct numbers and full diversity of neurons and glial cells 
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[248, 289]. This thesis provides evidence that Dmrt5 directly regulates Hes1 and has 
a role in neurogenesis of the ventral midbrain. 
The role of Hes1 in ventral midbrain development has only recently been described 
in three papers [243, 244, 290]. All papers find perturbation of Hes1 affect 
neurogenesis and cell proliferation in the ventral midbrain [243, 244, 290]. Ono et al 
showed that Nato3 is required for cell cycle progression and induction of proneural 
genes, Ngn2 and Mash1, in the ventral midbrain via repression of Hes1 [244]. This 
paper states that Hes1 expression is no longer detected at E10.5 and that this loss 
of Hes1 is mediated by direct repression by Nato3 [244]. Lahti et al, demonstrate that 
FGF signalling is needed for Hes1 expression in the ventral midbrain at E10.5 and 
E11.5. Loss of FGFR1/2 reduces Hes1 expression and results in premature 
neurogenesis and an increase in exit from the cell cycle [243]. In the third study, 
Hes1 null mice were analysed. These mice still develop some dopaminergic neurons 
expressing both Pitx3 and TH. However neurogenesis is precocious and depletion of 
the neural progenitor pool leads to a reduced number of dopaminergic neurons later 
in development [290]. As Hes1 has a role in formation of the IsO which is essential 
for correct formation of ventral midbrain [291], it is possible that some of these 
defects are due to loss of this structure. Although the details regarding the role of 
Hes1 in the ventral midbrain require further clarification the findings of this thesis are 
consistent with the current literature with up regulation of Hes1 seen upon 
exogenous expression of Dmrt5 affecting neurogenesis and cell proliferation. In the 
future conditional knock out of Hes1 in the ventral midbrain after formation of IsO will 
better define the role of Hes1 in ventral midbrain neurogenesis.  
The role of Nato3 and Hes1 in neurogenesis is postulated by Ono et al to be distinct 
from the previously described neurogenic network involving Lmx1A. This proposal is 
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based on the observation that in the absence of Nato3, midbrain dopaminergic 
neurons are correctly specified, expressing Lmx1A/B, Pitx3, Nurr1 and TH,  with only 
the number of neurons being affected [244].  Dmrt5 affects patterning and 
neurogenesis, further investigation will be required to determine if these two roles 
are distinct or interlinked.  
 
6.2 Dmrt5 as a general regulator of neurogenesis 
While there is little information regarding the role of Dmrt genes outside of sexual 
differentiation and development, what information there is indicates that Dmrt genes 
may have a conserved role in regulation of neurogenesis. Thus far, three 
publications have implicated Dmrt and Dmrt homologs in neurogenesis in Xenopus, 
Drosophila and C.elegans. This thesis describes the role of Dmrt5 in neurogenesis, 
in both the chicken and mouse, adding further support for this hypothesis.  
In Xenopus, Dmrt4 positively regulates genes involved in neuronal differentiation of 
the olfactory epithelium Xebf2, neurogenin and NCAM [225].  In C.elegans Dmrt 
homolog, Mab-3, represses Ref-1, a Hes1 homolog [292], to enable expression of 
proneural gene Lin32 (a Mash homolog) and V ray neurogenesis [242]. While in 
Drosophila, Dmrt homolog, Dsx, is known to regulate abdominal neuroblast 
differentiation [250].  
The mechanism by which neuronal markers are up regulated by Dmrt4 in the 
olfactory epithelium of Xenopus is not known. However, it may be possible that as 
postulated by Ross et al, regulation of neurogenesis by Dmrt proteins is mediated by 
regulation of Hes genes [242].  In support of this, expression of the male Drosophila 
DSXm, in C.elegans, rescues the Mab-3 mutant phenotype by inhibiting the ectopic 
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Ref-1 expression seen in Mab-3 mutants [192]. This suggests that these 2 proteins 
can both regulate the Hes1 homolog, Ref-1. As we learn more about the role of Dmrt 
genes outside of sexual development, studies will reveal if regulation of bHLH 
proteins and in particular Hes family members by DM domain transcription factors is 
a conserved mechanism.  
It is interesting to note that while Dmrt5 ectopic expression results in an increase in 
Hes1 expression and a subsequent reduction in neurogenesis. In C. elegans and 
Xenopus, loss of Mab-3 and Dmrt4 respectively inhibit neurogenesis, while ectopic 
expression of these genes promotes neurogenesis. These findings indicate that in 
these contexts Dmrt genes promote neurogenesis. Similarly in Drosophila in the 
absence of Dsx sex specific neuroblast fail to undergo divisions in male or female 
larval nervous systems suggesting that Dsx is required for generation of these 
neurons [250]. It will be interesting to investigate the effect of Dmrt5 loss-of-function 
on neurogenesis and why in the context of the midbrain Dmrt5 seems to have the 
opposite effect on neurogenesis.  
 
6.3 Is Dmrt5 transcription factor an activator or a repressor? 
Initial ChIP experiments demonstrate that Dmrt5 binds to the Hes1 promoter and that 
upon Dmrt5 exogenous expression Hes1 up regulation or ectopic expression is 
observed. These results suggest that Dmrt5 is directly activating expression of Hes1. 
This is unexpected for two reasons. Firstly in C.elegans, although Mab-3 directly 
regulates transcription of Ref-1, this is a direct repression of Hes1 homolog, Ref-1, 
rather than activation. Secondly, Dmrt5 is thought to be a transcriptional repressor as 
fusion of mouse Dmrt5 to VP16 activated transcription of targets in transfected 
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Hek293T cells [208]. Indeed, VP16 fusions to all 6 mouse Dmrt genes showed the 
same effect as Dmrt5, suggesting that Dmrt genes are repressors of transcription 
[208]. 
In support of our finding that Dmrt5 is acting as an activator of Hes1, there is 
evidence that Dmrt genes can act as both activators and inhibitors, depending on the 
tissue in which Dmrt genes are expressed [206, 242]. Furthermore, although Dmrt 
homolog in C.elegans, Mab-3, was found to repress transcription of Hes1 homolog, 
Ref-1. This repression was in part, hypothesised to be a result of antagonising 
activation by some unknown protein which binds to an overlapping site [242]. 
It is postulated that the binding of Dmrt proteins to the minor groove of DNA enables 
simultaneous binding of major groove factors to the same region of the enhancer 
element [206]. One example where this has been described is in Drosophila genes 
Dsx-f and Dsx-m, which can activate or repress expression of their transcriptional 
target Yp1 respectively [206]. Dsx-m has a longer C terminal domain which is 
proposed to occlude the binding site of a bZIP activator to the major groove. In 
support of this hypothesis, disruption of Mab-3 binding sites in the promoter of Ref-1 
prevents the activation of this gene, even though Mab-3 inhibits expression of Ref-1. 
This finding suggests that the activator binds in close proximity to the Mab-3 site, 
which may in turn indicate that Mab-3 represses Ref-1 by physically interfering with 
binding or function of activators bound to nearby sites [242]. The structure of Dmrt 
proteins may be particularly suited for interaction with transcription factors that bind 
overlapping sites of DNA, as Dmrt proteins bind to the minor groove [204] which 
could allow close apposition with major groove binding transcription factors.  
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In further support of the role of Dmrt5 in gene activation the results of the microarray 
show that 1229 genes are up regulated by ectopic expression of Dmrt5, while only 
229 are down regulated. Although not all of these changes will be the result of direct 
transcriptional targeting, one may have expected if Dmrt5 is solely a transcriptional 
repressor, that the number of down regulated genes would have been larger.  
In conclusion, it appears that Dsx can act as a repressor or an activator [206], and in 
the context of my thesis Dmrt5 appears to act as an activator.  
6.4 Dmrt5, an example of genes involved in midbrain dopaminergic 
neuron development.  
Like several other genes involved in ventral midbrain development, Dmrt5 seems to 
affect several processes, cell proliferation, cell patterning, and neurogenesis. The 
gene network in Figure 1.4 of Chapter 1 depicts a model of the regulatory network 
involved in development of midbrain dopaminergic neurons. Many genes involved in 
regulation of neurogenesis also function to inhibit the expression of more lateral 
fates, thus promoting a ventral phenotype. For example Lmx1A has been found to 
indirectly activate Ngn2, thus regulating neurogenesis [121]. Lmx1A also prevents 
expression of Red Nucleus (RN) fate specification genes [123]. Expressions of the 
genes involved in specification to RN fate inhibit dopaminergic fate and thus the 
repression of RN specification genes is crucial for correct neurogenesis of 
dopaminergic neurons. In particular Ngn1 expressed in the RN fate lineage 
represses Pitx3, a gene required for correct dopaminergic fate [123, 132]. FoxA2 in 
combination with Lmx1A is required for this inhibition of RN fate [123]. FoxA2 
therefore is another example of this mechanism. FoxA2 is involved in neurogenesis, 
via regulating Ngn2 expression, but also prevents expression of more lateral fates by 
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repressing Ngn1 [123], Nkx2.2 [124] and Helt [124] a gene expressed in neurons of 
GABAergic fate. A third example of this two pronged regulation of midbrain 
dopaminergic neuron development is Otx2 which regulates expression of Ngn2 and 
thus neurogenesis but also inhibits expression of Nkx6.1 which is expressed in more 
lateral regions [122, 139].   
Dmrt5 regulates expression of Ngn2 and neurogenesis, and microarray studies have 
also found that it represses expression of lateral fates, while significantly promoting 
expression of a ventral phenotype. Therefore Dmrt5 is another gene which fits this 
model and so is an example of the mechanisms by which midbrain dopaminergic 
specification genes give rise to dopaminergic neurons via regulation of Ngn2 and 
repression of more lateral fates. 
6.5 What initiates Dmrt5 Expression?  
This thesis investigates the role of Dmrt5 in ventral midbrain development and genes 
regulated by Dmrt5. However what triggers expression of Dmrt5 is not known. The 
expression of Dmrt5 starts in the anterior of the midbrain with posterior expression 
occurring later, this anterior to posterior pattern of expression mirrors the trend seen 
in the birth of TH expressing cells [293].  Genes with a similar spatial expression 
pattern that are expressed prior to Dmrt5, coupled with analysis of the region up 
stream of the Dmrt5 transcriptional start site for binding site of such genes may help 
to identify what activates expression of Dmrt5. Furthermore, investigation of the 
expression of Dmrt5 in mutant embryos such as FoxA2/1, Shh, Otx2, Lmx1A and 
Wnt null mice could help us to understand which genes/signalling pathways are 
involved in regulating Dmrt5. 
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6.6 Future directions 
Less neuron are seen when Dmrt5 is exogenously expressed both in the chicken 
midbrain and in epistem cell-derived neural cultures differentiated to dopaminergic 
fate as measured by antibody staining and real-time PCR, respectively. In 
agreement with this reduction in neurons, loss of proneural markers, such as Ngn2 
and Mash1, in combination with the reduction in cell proliferation is also seen. 
However this phenotype could also be caused by cell death. The findings from the 
microarray do not show an increase in the number of cell death genes in Dmrt5 over 
expressing ventral midbrain tissue compared to unelectroporated or mock 
electroporated controls. Furthermore, while a reduction in neuronal markers and 
markers involved in specification to dopaminergic fate are seen upon Dmrt5 
exogenous expression, the effect of Dmrt5 expression on TH has not been 
investigated. One would expect that there would be a reduction in the number of TH 
positive neurons, however this should be analysed.  
As discussed earlier in this Chapter there are some discrepancies regarding the 
temporal expression pattern of Hes1 during midbrain development. Ono et al show 
expression is below detection at E10.5, while Lahti et al show expression of Hes1 at 
E11.5. To better understand the regulation of Hes1 by Dmrt5, the expression pattern 
of both of these genes should be investigated further by double in situ or antibody 
staining. Furthermore, while I have mapped the expression pattern of Dmrt5 during 
the time window of specification and differentiation of the ventral midbrain to 
dopaminergic neurons further investigation of Dmrt5 expression both earlier and later 
in development should be carried out to identify any other roles of this gene.  
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To complement these gain of function studies which provide insight into the possible 
functions of Dmrt5, loss of function studies are also essential. A Dmrt5 heterozygous 
mouse has recently been generated in the lab, and is currently being studied. 
Interestingly in the Dmrt5 knock out cell line, cells differentiated to dopaminergic fate 
also show an up regulation of Hes1 (Nicole Gennet). This suggests that there is an 
added complexity in the regulation of Hes1 by Dmrt5 during midbrain dopaminergic 
neurogenesis.  The neurogenic effect of loss of Dmrt5 has not yet been investigated 
further.  
On a conceptual level inhibiting neurogenesis in cells just as this process is being 
initiated is counterintuitive. However, as is seen in the Hes1 mutant this is an 
essential process required to ensure that the progenitors continue to divide and thus 
give rise to the correct number of neurons. Based on the findings of this thesis I 
would propose that Dmrt5 functions to maintain neural progenitors and prevents their 
terminal differentiation via its regulation of Hes1. Further studies are required to 
confirm this.  
The microarray data presented in this thesis provides a rich source of information for 
future studies. The biggest challenge when analysing this is to decide what 
questions to ask in order to find meaningful results which will help further our 
understanding of Dmrt5. One important study would be to identify genes directly 
regulated by Dmrt5. To achieve this, the genes up and down regulated by Dmrt5, as 
found by microarray analysis, should be analysed to find those which contain Dmrt5 
consensus binding sites. This candidate list of Dmrt5 target genes can be further 
refined by identifying which of these are also found in microarray data from the over 
expression and knock down of Dmrt5 in dopaminergic neurons derived from 
embryonic stem cells in vitro. Whilst the differentiation of embryonic stem cells to 
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dopaminergic fate may lack some of the developmental patterning and possibly 
cofactors required for correct Dmrt5 function, comparison of this data to the in vivo 
over expression of Dmrt5 may help to refine the genes which are directly regulated 
by Dmrt5. Furthermore, ChIP Seq experiments could be carried out to identify more 
direct targets of Dmrt5. 
With regard to the FP data from the chicken embryo collected at HH st 16, 
comparison of this to microarray data obtained in the lab from the FP of mouse at 
E9.5 can be used to identify both similarities and differences in the transcriptional 
profile of this tissue across species. Genes conserved in both species and so far 
unknown in this region may provide good candidates for future investigations into 
genes involved in midbrain dopaminergic neuron development.  
While this thesis concentrated on identifying a role of Dmrt5 in midbrain 
development, the microarray data provide useful information regarding the function 
of Dmrt5 in other tissues. This is because it provides a list of genes which are 
regulated, directly or indirectly, by Dmrt5. For example in Chapter 3, I identified that 
Dmrt5 is expressed in the optic placodes and the lens of the developing chicken 
embryo. From the microarray analysis I found Dmrt5 ectopic expression leads to the 
up regulation of many genes involved in axon guidance. One of these genes 
Sema3A is expressed in the lens and is required for correct eye development [294]. 
Sem3A signalling from the lens segregates periocular neural crest into 2 lineages. A 
Npn-1 negative lineage which  is essential for periocular neural crest migration and 
formation of the cornea and a npn1 positive lineage which is needed for formation of 
anterior uvea and periocular tissues [239]. Since Dmrt5 is expressed in the lens and 
up regulates Sema3A it may be involved in this process. My data set could be of use 
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for those interested in the formation of other Dmrt5 expressing tissues such as the 
eye, telencephalon, optic stalk nasal placodes and pituitary.   
6.7 The significance of the findings presented in this thesis. 
Although a collection of genes are known to be involved in neurogenesis of the 
ventral midbrain, our understanding of the mechanisms causing neurogenesis in this 
region is still incomplete. Dmrt5 is expressed in the region from which midbrain 
dopaminergic neurons arise within the ventral midbrain, in the same region as Hes1. 
Here we show Dmrt5 binds to the promoter region of Hes1 and can ectopically 
induce Hes1 expression. Furthermore Dmrt5 affects cell proliferation and 
neurogenesis, both of these processes are also affected by Hes1, implying the 
effects observed upon Dmrt5 over expression may in part be mediated via regulation 
of Hes1.  Dmrt5 also causes the down regulation of Nato3, a gene known to repress 
Hes1 expression and induce neurogenesis.  As such Dmrt5 is a new member of the 
neurogenic pathway of the ventral midbrain. Furthermore, microarray screens 
followed by candidate validation by real-time PCR showed that Dmrt5 promotes a 
ventral transcriptional profile. Therefore Dmrt5 is a gene involved in three 
fundamental aspects of ventral midbrain development: patterning, neurogenesis and 
cell cycle of ventral midbrain neurons. The information in this thesis improves our 
understanding of the genes involved in dopaminergic neuron development. This 
information can be employed to improve current in vitro midbrain dopaminergic 
differentiation methods so that phenotypically correct dopaminergic neurons can be 
created in vitro efficiently. These can be used for disease modelling, drug screens 
and even transplantation.  
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